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ABSTRACT
Background: Aims of the study were: (i) to characterise the clinical picture, 
immunological features and changes in brain morphology and function in 
patients with widespread unilateral pain and HSV-infections (I, II), and (ii) to 
analyse the prevalence, clinical symptoms and immunological predisposing 
factors of HSV-2 induced recurrent lymphocytic meningitis (RLM) in Southern 
Finland (III, VI).
Methods: Patients for the studies were recruited from the Pain Clinic, 
Department of Anaesthesiology and Intensive Care Medicine, from the 
Division of Infectious Diseases, Department of Medicine, and from the 
Department of Neurology, Helsinki University Central Hospital. Controls 
for laboratory analyses were recruited from the Vita Laboratories, Helsinki, 
Finland. Plasma concentrations of IgM, IgA, IgG, and IgG1-4, serum 
concentrations of C3, C4 and serum classical pathway hemolytic activity 
(CH50) were measured (I and IV). Serological anti-HSV-1 and -2 antibody 
status was tested (I and III). C4 phenotyping, and the analyses of C4 gene 
copy numbers by isotype-specific genomic real-time PCR amplification, HLA-
A, HLA-B and HLA-DRB1 typing (I and IV), MBL2 genotyping (IV), and IgG1 
and IgG3 allotyping (Gm) (I and IV) were performed. Clinical neurological 
examination (I-IV), quantitative sensory testing (I and II), skin biopsy (I), and 
functional magnetic resonance imaging (II) were also performed.
Results: We found support to our hypothesis that HSV, or inflammatory 
reaction triggered by the virus, has a role in the generation of a 
pathological pain state. We characterized the clinical picture of the patients 
with widespread unilateral pain and present found subtle immunological 
abnormalities, including low serum IgG1 and IgG3 levels, which made the 
patients vulnerable for recurring HSV infections. We also demonstrated 
both functional and structural changes in the brain pain-processing areas 
in these patients: they had less pain-related activity in the insular cortices 
(IC) bilaterally, in the anterior cingular cortex (ACC), and in the thalamus, 
and the gray matter density was lower in the ACC, and in the frontal and 
prefrontal cortices.
In the meningitis studies we presented a period prevalence of RLM, 
showed that RLM is more common and less benign than previously reported, 
and that neuropathic pain is frequently present both during and after 
meningitis episodes. We also showed that HLA-DRB1*01, HLA-B*27, and 
low IgG1 levels are predisposing factors for RLM. 
Conclusions: Patients are vulnerable to recurrent HSV infections because 
of subtle immunological abnormalities. HSV causes diverse clinical 
manifestations. First, the herpes simplex virus, or the inflammatory process 
10
triggered by it, may cause pathological widespread pain probably by 
activating glial cells in the CNS. In these patients, signs of alterations in 
the brain pain-processing areas can be demonstrated by functional brain 
imaging methods. Secondly, HSV-2 induced RLM is a rare complication 
of HSV-2 virus. The predisposing factors include low IgG1 subclass levels, 
HLA-DRB1*01 and HLA	 -B*27 genotypes. Neuropathic pain is frequently 
associated with RLM.
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1. Introduction
Pain in an unpleasant experience associated with actual or potential tissue 
damage by noxious stimuli. It includes not only the conscious perception of 
the sensory event, but also the cognitive analysis and emotional response 
associated with the experience. Acute pain has an adaptive function. It 
makes us move away quickly from the pain-inducing stimulus, and teaches 
us to avoid pain inducing dangers in the future. While becoming chronic, 
the pain looses its adaptive function, and becomes harmful.154
Pain is characterized as chronic when it is present for longer than six 
months. Chronic pain may be classified as nociseptive, neuropathic or 
idiopathic. Nociseptive pain arises, when the nociceptors in the skin, muscles, 
joints and viscera are stimulated by pressure, heat, irritant chemicals etc., 
whereas neuropathic pain arises as a consequence to a lesion or a disease 
of the somatosensory system. In idiopathic pain, the aetiology of chronic 
pain remains unsolved.138 
The term “pathological pain” is occasionally used, when speaking about 
debilitating, chronic, widespread – and often neuropathic – pain. It is 
characterized by an amplified response to normally innocuous stimuli, and 
an amplified response to acute pain. Pathological pain is not adaptive, and 
it may not be limited to the area of damage. Body regions beyond the site 
of damage may also exhibit exaggerated pain responses although they are 
not innervated by the damaged nerves, i.e. the pain is extra-territorial. In 
addition, a small proportion of patients may also report pain as arising from 
the corresponding body part on the healthy contralateral side of the body. 
That is, the exaggerated pain is “mirrored” on the other side, and called as 
“mirror-image” pain.90, 125, 154
Long-lasting neuropathic pain is often pathological. The treatment 
of neuropathic, as well as pathological pain is challenging. Neuropathic 
pain responds poorly to nonsteroidal anti-inflammatory drugs, and only 
moderately to opioids. Patients may get relief from drugs that are targeted 
to neurons, but the relief is usually only partial – a 30% reduction in pain 
is considered as a moderate to good result.36, 63 One reason for failures 
in drug therapy may be that drugs are targeted to neurons, whereas 
immunologically active glial cells, which are considered to be important in 
both induction and maintenance of pathological pain states, are ignored.143, 
154
Glia is activated by different pathogens (including bacteria and viruses), 
infections, and inflammation. The activation of glial cells is followed by 
release of inflammatory mediators from the peripheral nerve endings, which 
may further activate other glial cells. This is supposed to cause the spread 
of pain in extraterritorial, and mirror-image pain.144, 147
Herpes simplex viruses 1 and 2 are among the most common viruses 
causing infections in man. They are neuroinvasive, they have an ability to 
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maintain latency in the nervous system after primary infection, and they 
are able to periodically reactivate from their latency.119 Because of their viral 
properties, herpes simplex viruses are good candidates for activating glia. 
Microglia has been shown to detect HSV, most likely via Toll-like receptors, 
and induce the release of cytokines, including tumor necrosis factor-α, as 
an attempt to defend agaist the virus.10, 37, 101
Viral reactivations become clinically evident only in a minority of patients. 
The severity of disease manifestations depends on a variety of virus and host 
factors. Immune competence seems to be crucial to the maintenance of 
latency. Some individuals may be more vulnerable to severe manifestations 
and frequent reactivations of HSV due to defects in cell-mediated immunity, 
as e.g. transplant recipients and patients with AIDS.109, 115
Clinical manifestations of HSV-1 and HSV-2 are diverse. In addition 
of probably being able to activate glia and to induce pathological pain, 
one rare manifestation of HSV is recurrent lymphocytic meningitis (RLM). 
It is a seldom seen disease, mostly caused by HSV-2. There is significant 
patient-to-patient variability regarding the time to recurrence and the 
total number of episodes. Patients are most often young or middle-aged, 
and women are more often affected.116 RLM is considered a benign disease 
with no neurological sequelae. Neuropathic pain in association with RLM 
has only rarely been reported.12 Predisposing factors for RLM are not known. 
There is one case report of RLM associated with Ig-sublass deficiency, and 
in another study, an association between MBL deficiency and RLM has 
been implied.122,128 It has also been suggested that complications of HSV 
infections are more common when the infection is primary, instead of initial. 
In developed countries, seroprevalence to HSV-1 has decreased, and so a 
larger proportion of HSV-2 infections in the future will be primary.22 Thus, 
RLM may be more common in the years to come.
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2. Review Of The Literature
2.1. The neuroanatomy of pain
The first documented attempt to understand pain, was done by Rene 
Descartes, a philosopher and scientist, who in 1664 introduced a theory of 
pain transmitted through a single channel from the skin to the brain (Figure 
1). This simplified theory directed both the theory and the treatment of pain 
for more than 300 years.24 Today we know that pain transmission is much 
more complicated.
Figure 1. Rene Descartes: Tractatus De Homine 1664.
Peripheral afferents
The sensory experience begins in the periphery, where the peripheral 
terminals of primary afferent fibers respond to stimuli. There are three 
main types of these fibers. Aβ-fibers are large in diameter and highly 
myelinated fibers with low activation threshold. They respond to light touch 
and quickly conduct tactile information to spinal cord. Aδ-fibers are smaller 
in diameter and only thinly myelinated. They are slower than Aβ-fibers, 
and have a higher activation threshold. They respond to both thermal 
and mechanical stimuli. C-fibers are the smallest type of afferent fibers, 
they are unmyelinated, and thus also the slowest fiber type. They have the 
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highest activation threshold, and respond only to nociceptive stimuli.31 The 
Aδ- and C-fibers are called nociceptors. Tissue damage or inflammation can 
excite the peripheral terminals of these nociceptors, causing the release of 
endogenous chemical mediators, such as prostaglandins, bradykinin, and 
substance P. These substances may then sensitise the nociceptors so that the 
afferent activity to a given stimulus increases. This phenomenon is called 
primary hyperalgesia.24, 31
dorsal horn
Aδ- and C-fibers synapse to the spinal cord dorsal horn, which is organised 
into different laminae. Most nociceptive fibers terminate to superficial 
laminae I-II. In the spinal cord dorsal horn there are various neuronal cell 
types which respond to different sensory stimuli. Nociceptive specific cells 
are mostly found superficially, and synapse with Aδ- and C-fibers only. Wide 
dynamic range (WDR) neurons receive information from all three types 
of sensory fibers (Aβ, Aδ, C) and therefore respond to all kind of stimuli 
from light touch to noxious pinch, heat and chemicals. In addition, there 
are excitatory (glutamatergic), and inhibitory (GABAergic) interneurons 
in the spinal cord, which are able to increase or decrease the response 
of the nociceptive and WDR neurons. In addition to these, evidence has 
accumulated during the last decade suggesting that also non-neuronal cells 
of the dorsal horn (astrocytes and microglia) influence pain transmission 
through the dorsal horn, particularly under pathological conditions.31
spinal cord
Neuronal activity in the spinal cord dorsal horn is under dynamic modulation; 
messages received by the spinal cord may be suppressed, relayed unaltered, 
or amplified. The relationship between the stimulus and response to pain is 
not always linear, spinal neurons which respond to nociceptive information 
are under constant control by peripheral inputs, interneurons, and 
descending controls. The response may also be greatly altered by various 
neurotransmitter systems, particularly during pathological conditions.154 
Ascending and descending pathways in the spinal cord
Signals from the dorsal horn to supraspinal structures are carried by spinal 
projection neurons along the ascending pathways. The most prominent 
ascending pathway is the spinothalamic tract (STT), which transmits 
sensations of pain, temperature, and touch. It crosses the midline at the 
spinal nerve level, and ascends in the ventrolateral funiculus (VLF) to the 
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thalamus. The second pathway is the spinomesencephalic tract (SMT). It 
also crosses the midline, and ascends in the VLF to midbrain, especially 
periaqueductal grey (PAG) and nucleus cuneiformis. The third tract is the 
spinoreticular tract (SRT), which terminates in the reticular formation of 
the medulla. In addition to the primary target structures, the ascending 
pathways also project to the brainstem area, such as the rostral ventromedial 
medulla (RVM), which has descending pathways back to dorsal horn.106 
Activation of the descending pathways from the brainstem modulates 
the pain experience, and is influenced also by limbic areas, hence adding 
the emotional, affective component to the pain experience. The descending 
pathways may be both facilitatory and inhibitatory. Descending facilitatory 
pathways from the brainstem RVM have been shown to be involved in the 
maintenance, but not in the initiation, of nerve injury induced pain. This 
facilitatory descending tract modulates neuronal responses to tactile stimuli 
in the dorsal horn, and may be behind mechanical allodynia.31 
Descending inhibitory actions involve the release of noradrenaline, 
which inhibits transmitter release from primary afferents, and the release 
of substance P in the dorsal horn suppressing the projection neurons. This is 
accomplished by interneurons, and indirectly by the release of endogenous 
opioids, and is an endogenous system for pain control.24 
Both descending facilitatory and inhibitory noradrenergic projections 
undergo plastic changes in chronic pain states, like an increase in descending 
noradrenergic inhibition after peripheral inflammation (Figure 2). 
Figure 2. Dynamic modulation of pain. CNS contains distinct circuits that either inhibit 
or facilitate pain. Inhibitory systems are activated by opiate drugs, environmental 
factors, and learned danger signals. Facilitatory systems are activated by infection, 
inflammation, and learned sickness and safety signals. Pain inhibitory systems suppress 
pain by inhibiting neurons in the spinal cord dorsal horn, and pain facilitatory systems 
exaggerate pain by increasing excitability in these neurons. There is also dynamic 
modulation of the release of neurotransmitters from pain fibers arriving in the spinal 
cord. The Figure is modified from Watkins LR and Maier SF. The pain of being sick. 
Annual Review of Psychology 2000;51:29-57. 
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the thalamus
The thalamus is the main relay site for nociceptive information to cortical 
and subcortical structures. Within the thalamus, nociceptive information 
regarding the type, intensity, and location of pain is encoded prior to 
sending the information onward to limbic structures and cortex.106 
The lateral pain system consists of STT neurons projecting through the 
ventral posterolateral (VPL) nucleus of the thalamus to the primary and 
secondary somatosensory cortex (SI and SII), to parietal operculum, and to 
the insula. It is mainly associated with the sensory-discriminative aspects of 
pain processing, and provides information on stimulus location and intensity. 
The medial pain system includes the STT neurons projecting through the 
posterior ventromedial (VMpo) nucleus of the thalamus, and further to 
the ACC, amygdala, hippocampus, hypothalamus, parabrachial nuclei and 
to periaqueductal gray (PAG). It plays a crucial role in the motivational-
affective and cognitive-evaluative aspects of pain processing.15, 73 Functional 
and anatomic divisions of the thalamus have been made on the basis of their 
connections to specific spinal cord laminae. The relevance of anatomically 
defined thalamic nuclei has also been confirmed in humans with high-
resolution imaging studies: direct stimulation of the principal somatosensory 
nucleus (Vc) in human thalamus produces two types of pain responses: an 
on-off type signalling of the presence of painful stimulus, and a firing rate 
signalling of the intensity of painful stimuli.19 
Thalamus is implicated in chronic pain, and thalamic hypoperfusion 
reflects the pain state. In cancer pain patients, decreased blood flow 
contralateral to pain has been registered.28 In neuropathic pain it has 
been argued that hypoperfusion of the thalamus could also reflect 
deafferentation. On the other hand, in one study of deafferentation-related 
pain, thalamic hypoperfusion was restored following pain relief.44 
The pain pathways from periphery to the brain are seen in Figure 3.
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Figure 3. Pain pathways from periphery to brain. Primary afferent fibers transmit 
impulses from the periphery, through the dorsal root ganglia (DRG) to the dorsal horn 
in the spinal cord. Nociceptive specific (NS) cells are mainly found in the superficial 
dorsal horn (laminae I-II), whereas most of the wide dynamic range cells (WDRs) are 
located deeper (lamina V). Projection neurons from lamina I innervate areas such as 
the parabrachial area (PB) and periaqueductal grey (PAG), and are affected by limbic 
areas. Descending pathways from brainstem modulate spinal processing. Lamina 
V neurons mostly project to the thalamus, and from there to the various cortical 
regions, including SI, SII, IC, ACC, and PFC. The Figure is reprinted from D’Mello R 
and Dickenson AH. Spinal cord mechanisms of pain. British Journal of Anaesthesia 
2008;10:8-16 with permission of Oxford University Press and the authors.
central processing of pain 
Pain is a complex, multi-factorial subjective experience, and its measurement 
and imaging are difficult. A large brain network is subsequently active 
during nociceptive processing. Melzack (1999) first described the term pain 
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“neuromatrix”, now more commonly called “pain matrix”. It means all brain 
regions, which have more or less active roles in sensory-discriminatory or 
affective-cognitive-evaluative components of pain.85, 86, 133
There are several meta-analyses available of human data from positron 
emission tomography (PET), functional magnetic resonance imaging 
(fMRI), electroencephalography (EEG), and magnetoencephalography 
(MEG) providing evidence of the most common regions active in an acute 
experimental pain (Figure 4).133 Five major cortical areas have been identified 
consistently responding to acute pain. These areas include the primary and 
secondary somatosensory cortices (SI and SII), the insular cortex (IC), the 
anterior cingulate cortex (ACC), and prefrontal cortices (PFC). 
The ACC is reported as the area most often activated by different noxious 
or painful stimuli; also the IC is generally activated. Neurons in the ACC 
and IC are likely to encode multiple forms of pain. Results from human 
brain imaging studies suggest that not all pain is processed by similar 
brain regions, and each particular form of pain is coded by several brain 
regions.133, 157 In addition, there are other regions which may be active 
especially in chronic pain; such as basal ganglia, cerebellum, amygdala, and 
the areas within the parietal and temporal cortices.133 
Pain-related somatotopy has been observed in the contralateral insula, 
where face activation was anterior to both hands and feet, and in the SI 
cortex, where the organization follows the same somatotopy as observed 
for tactile input.8, 15
Less is known about clinical/chronic pain than of experimental acute pain. 
In studies of acute pain in healthy subjects, the stimulus is easily controlled 
and healthy subjects are easy to find. On the contrary, the chronic pain 
patients are heterogeneous, and many factors affect the evaluation of pain 
they report. Despite this, some information of chronic pain in patients is 
available. 
Sustained high level of spontaneous pain results in increased activity 
within the medial PFC and the ACC.127 Activation in rostral anterior insula 
and PFC is consistently seen in clinical pain conditions, irrespective of 
underlying pathology. It has been suggested that clinical pain is located 
more rostrally in the anterior insula than nociceptive pain in healthy 
volunteers.113 It seems that especially the middle short gyrus in the anterior 
part of insular cortex is implicated in processing chronic pain.2 The anterior 
insula is active not only during pain, but is also associated with anxiety, 
depression, fatigue, fibromyalgia, somatization and fear. 
Both activation and deactivation of different brain areas seem to be 
crucial. Deactivation of cortical areas may reflect a reduction in neuronal 
activity. It might mean that excitation and inhibition occurs not only at the 
neuronal level, but also at the cortical network level.157 It is not known if 
deactivation occurs only at the inhibitory neurons, thus reflecting decreased 
pain inhibition as a cause of chronic pain. Gabapentin, a drug commonly 
used to treat neuropathic pain, has been shown to reduce chronic pain-
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related deactivation, suggesting that deactivation might, indeed, contribute 
to chronic pain.59 
A variety of brain regions are involved in the descending modulation 
of pain. These areas include the frontal lobe, ACC, insula, amygdala, 
hypothalamus, PAG, nucleus cuneiformis, and RVM. This is one way for the 
brain to alter pain processing, and perhaps the route by which sleep, anxiety, 
coping, and catastrophizing may impact the pain experienced.31 Attention, 
mood and emotional state have a significant impact on the resultant pain 
perception and the ability to cope. Cerebral neuronal plasticity may underlie 
all these conditions. A common clinical and experimental observation is 
that anticipating and being anxious about pain can exacerbate the pain 
experienced. Anticipating pain is adaptive in acute pain, but in chronic pain 
it becomes maladaptive, and can lead to fear of movement, avoidance, and 
anxiety. We are only beginning to unravel the specific roles of different 
brain areas in pain processing and pain-related phenomena like depression 
and anxiety.133 
Chronic pain may cause structural changes in the brain. In chronic back 
pain patients, decreased prefrontal and thalamic gray matter density has 
been demonstrated.9 In fibromyalgia patients, there is a loss of gray matter 
in the ACC, IC, PFC and parahippocampal gyri.72 It is unclear whether the 
loss of neurons is limited to local inhibitory neurons. Furtherrmore, it is 
unclear whether these structural changes are a consequence of chronic 
pain or of secondary changes due to pain-related mental disorders, such 
as depression.157 
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Figure 4. Main brain regions that are activated during a painful experience, 
highlighted when bilaterally active. Orange, when increased activation on contralateral 
hemisphere. The Figure is reprinted from Tracey I and Mantyh PW. The cerebral 
signature for pain perception and its modulation. Neuron 2007;55:377-391 with 
permission from the publisher.
2.2. Cellular and synaptic mechanisms of chronic pain
transmitters
Suppression of pain is essential in life-threatening situations, when in spite 
of tissue damage the animal has to be able to escape. During that kind 
of intense stress, pain-suppressing neurotransmitters (endorphins) are 
released. Endorphins can act within the spinal cord dorsal horn, and prevent 
nociceptive signals from reaching the brain. 
On the other hand, nociceptive information may be amplified, often 
as a result of increased nerve excitability, resulting in exaggerated pain 
responses. Increased sensory nerve excitability increases the release of 
glutamate and substance P, which are the classic pain neurotransmitters in 
the spinal cord. Glutamate is an excitatory amino acid expressed throughout 
the nervous system. This neurotransmitter is essential for pain signalling 
at all anatomical levels. The majority of primary afferents synapsing in the 
dorsal horn utilize this transmitter. The main inhibitory transmitter in turn 
is gamma-aminobutyric acid (GABA).31, 157
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Herpes Simplex Virus Infection, Pathological Pain and Recurrent Lymphocytic Meningitis 21
receptors
Glutamate exerts its excitatory effect via different receptor subclasses: AMPA 
receptors, NMDA receptors, mGluR receptors, and Kainate receptors. Most 
is known about the function of AMPA and NMDA receptors. During acute 
or persistent noxious stimulus glutamate is released from the peripheral 
terminals. AMPA receptors are activated to the stimulus first, and set the 
baseline response in the dorsal horn. With repetitive and high-frequency 
stimulation of the C-fibers, the NMDA receptors are activated. Activation 
of the NMDA receptors is not possible with only acute or low-frequency 
noxious stimuli. It is likely that the co-release of peptidergic transmitters, 
such as substance P and CGRP (calcitonine gene related peptide) are needed 
to activate NMDA. Hence, NMDA receptor activation has been shown to 
be in a key role in hyperalgesia, or enhancement of pain seen in chronic 
pain states such as neuropathic pain. Activation of NMDA receptors leads 
to an increase in postsynaptic calcium ions (Ca 2+) and to influx of Ca 2+ to 
the cell. Once inside, Ca 2+ serves as an important intracellular signal for 
triggering, of e.g. neuronic nitric oxide (NO) syntheses, which in turn can 
promote mechanisms of plasticity, such as long-term potentiation. Overall, it 
is likely that aberrant activity is amplified and enhanced by NMDA receptor-
mediated mechanisms in tissue damage and neuropathic pain, and that this 
receptor is critical for both the induction and maintenance of pain.31, 157
2.3. Genetics and pain
Several genetic variants that either prevent, decrease or increase pain have 
been identified in humans. Examples of variants which increase pain include 
the δ-opioid receptor genetic variant OPRD1, which is known to increase 
pain sensitivity, and variants in cytochrome P450	 (CYP)	 2D6, which are 
associated with decreased codeine effects. Genetic variants, which reduce 
pain, can either prevent it completely, almost completely, or they may 
increase analgesic drug effects, thus reducing pain. 
Complete prevention of perceiving of pain has so far been reported 
in six different rare hereditary syndromes, namely the “channelopathy-
associated insensitivity to pain”, and in five distinct hereditary sensory and 
autonomic neuropathies (HSAN I-V). Channelopathy patients suffer from a 
loss of affective-motivational component of pain perception. They recognize 
the painful stimuli but do not show any withdrawal responses. In these 
patients, the mutation is in SCN9A	gene, which codes the voltage-gated 
sodium channel (Nav1.7). HSAN patients have peripheral neuropathy, they 
have a sensory-discriminative deficit and do not perceive pain. Five types of 
HSAN are caused by mutations in five distinct genes (SPTLC1,	HSN2,	IKBKAP,	
NTRK1 and NGFB).29, 30, 95 
Genetic variants that decrease pain have been identified in healthy 
22 Review Of The Literature
individuals, without any hereditary syndrome. These variants only 
moderately modulate the expression or function of the biological structures. 
A variant in μ-opioid receptor gene (OPRM1) is associated with a decrease 
in pressure pain intensity. A variant in COMT gene is associated with a 
reduction in the activity of an enzyme, which metabolizes catecholamines 
(e.g. dopamine, norepinephrine and epinephrine), thus having an effect in 
pain transmission.29, 30, 95 Genes may also influence nociceptive processing 
in the brain: in a PET study, individuals homozygous for the met158 allele 
of the COMT polymorphism showed diminished regional μ-opioid system 
responses to pain, and higher sensory and affective ratings of pain compared 
with heterozygotes.133, 158 In addition, there are gene variants, which 
decrease pain by increasing analgesic drug effects, e.g. the cytochrome 
P450	2D6 gene, which increases the metabolism of prodrugs into active 
analgesics.29, 30, 95
Associations between genotype and phenotype in pain have been 
difficult to reproduce (e.g. COMT), probably because of high frequency of 
pain-relevant genetic variants in healthy population.79 In epidemiological 
studies, genetic factors are thought to account for half of all low back pain 
heredibility.56 
Because of the strong linkage disequilibrium in the MHC region, 
associations between HLA haplotypes and pain are difficult to identify, 
and large population-based studies are needed. In Japanese patients, 
HLA haplotype HLA-A*3303-B*4403-DRB1*1302 has been shown to 
be associated with an increased risk to develop neuropathic pain after 
herpes zoster infection, but not with the onset of herpes zoster.110 TNF 
gene in the MHC region codes cytokine TNF-α, which induces hyperalgesia. 
It has been suggested that polymorphisms in genes in the MHC region 
may be associated not only with autoimmune diseases, but also with the 
susceptibility to develop neuropathic pain.123
2.4. Neuropathic pain
According to a new definition, neuropathic pain is “pain arising as a direct 
consequence of a lesion or disease affecting the somatosensory system”. 
Because of lack of a specific diagnostic tool for neuropathic pain, a grading 
system for definite, probable, and possible neuropathic pain has been 
proposed (Figure 5). The former IASP (International Association for the Study 
of Pain) definition date back to year 1994: neuropathic pain is “initiated 
or caused by a primary lesion or dysfunction in the nervous system”. The 
problem with this definition was that it lacked defined boundaries. Indeed, 
the sensitivity of nociceptive system is modulated by its adequate activation 
(e.g. central sensitization), so it is difficult to distinguish neuropathic 
dysfunction from physiologic neuroplasticity.21, 134
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Figure 5. A grading system for neuropathic pain: Diagnostic criteria for possible, 
probable and definite neuropathic pain. Modified from Figure of Treede RD et al. 
Neuropathic pain: redefinition and a grading system for clinical and research purposes. 
Neurology 2008;70:1630-1635.
Neuropathic pain is characterized as pain in the absence of a stimulus. 
Nociceptive thresholds are reduced, so that normally innocuous stimuli 
produce pain. Stimuli may also evoke abnormal or unpleasant perceptions 
of pain (paraestehesia, dysesthesia). Neuropathic pain arises from trauma, 
inflammation or infection of peripheral nerves. Traditionally neuropathic 
and inflammatory pain were considered distinct entities. Today, however, 
infection or inflammation is estimated to be responsible for up to half of all 
cases of neuropathic pain, and the immune system is considered to actively 
participate in creating and maintaining neuropathic pain conditions of 
diverse aetiologies (Figure 6).112, 145, 146 
Neuropathic pain should be divided into peripheral or central neuropathic 
pain based on the anatomic location of the lesion or the disease. Most (90%) 
neuropathic pain states have been considered to arise from the peripheral 
rather than the central nervous system.33 Examples of peripheral neuropathic 
pain states include polyneuropathies of various aetiologies, postherpetic 
neuralgia, and iatrogenic or traumatic injuries. Central pain syndromes 
represent a form of neuropathic pain that is associated with lesions of the 
brain or the spinal cord. The most common aetiologies are stroke, traumatic 
spinal cord injury or multiple sclerosis.93 
In neuropathic pain the activity, properties, and transmitter contents 
of the nerves change.31, 121 Animal models of inflammatory and traumatic 
neuropathy have revealed a remarkable degree of plasticity in sensory 
nerves, sensory nerve somas, and the spinal cord. Damaged nerves may 
develop spontaneous activity in peripheral nerve terminals, on axonal level 
and in neuronal cell bodies, and become increasingly actively responsive to 
pain-inducing substances. Ectopic activity is due to the accumulation and 
clustering of sodium (Na+) channels around the damaged axon. This aberrant 
activity may spread to the cell bodies in the dorsal root ganglia. Nerve 
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fibers may also start to cross-excite each other. In addition, sympathetic 
efferents may start to activate sensory afferents, which results in spreading 
of excitation between different cell types.143
Figure 6.  In up to half of the cases neuropathic pain is caused by infection or 
inflammation. In addition, inflammatory mechanisms are often activated in 
neuropathic pain.
2.5. The immune connection in neuropathic pain and 
the role of glia 
Previously pain was thought to be mediated solely by the neurons. During 
the last decade it has became evident that spinal cord glia (astrocytes and 
microglia) plays an important role in exaggerated, pathological pain (Figure 7). 
Glia was first suggested a contributing factor to pathological pain by Garrison 
et al. in 1994. They found that (i) manipulation that creates pathological pain 
also activates astrocytes, and (ii) a drug that blocks pathological pain also 
blocks astrocyte activation. Since then, every animal model of pathological 
pain has revealed a positive correlation between exaggerated pain and 
activation of spinal cord glia.46, 154
Activation of glia is necessary for both induction and maintenance of 
pathological pain. Microglia and astrocytes may have a distinct role in 
pathological pain. It has been proposed that early activation of microglia 
leads to activation of astrocytes, which serves to maintain pathological 
pain.105 Exaggerated pain may be blocked by blocking the activation of spinal 
cord glia.90 Similarly, development of exaggerated pain may be blocked by 
administration of a microglia specific inhibitor, minocycline.132 
Glial cells (but not neurons) are immunocompetent cells. Glia is activated 
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by several substances, including viral pathogens, as well as by excitatory amino 
acids and prostaglandins, which activate also neurons. Selective activation of 
only glia is possible by using foreign invaders like viruses, which bind to specific 
receptors in glia. It has been shown that glial activation, without neuronal 
activation, is sufficient to induce exaggerated pain states.88 Microglia has been 
shown to be able to detect HSV, most likely via Toll-like receptors. In response, 
it releases proinflammatory cytokine TNF-α and upregulates GLT-1 (glutamate 
transporter), leading to increased microglial glutamate uptake.101
Glia is not involved in acute pain. Normally glia is quiescent and releases 
nothing that enhances pain. Once activated, it releases substances that 
essentially contribute to the amplification of pain.88
Neurons are able to release classical pain neurotransmitters (EAA, substance 
P, prostaglandins, ATP, and NO, among others), thereby activating glia in	
vivo. When activated, glia activates other glial cells by releasing excitatory 
substances like interleukin-1β and NO. As immunocompetent cells, activated 
glia releases classical immune proteins including proinflammatory cytokines 
(IL-1β, IL-6, TNF-α). In the spinal cord these proinflammatory cytokines are 
signal molecules that activate neurons as well as glia, and thus glia can signal 
neurons. Blocking of proinflammatory cytokine activation in the spinal cord 
blocks diverse exaggerated pain states.155
Theoretically, the release of pain enhancing substances by newly activated 
astrocytes distant from the initial site of trauma could explain the spread of 
pain as ”mirror image pain” and “extraterritorial pain”. Astrocytes are able 
to communicate with each other via gap junctions. In animal models, spread 
of pain has been blocked by spinal administration of substrates that disrupt 
gap junctions.125, 144, 147
Glial cells also compromise the ability of opioids to suppress pain. Evidence 
exists that chronic morphine activates both astrocytes and microglia, and that 
it also activates microglial p38 MAP kinase and stimulates the production 
of spinal proinflammatory cytokines. Morphine tolerance is attenuated 
or reversed by either inhibition of spinal proinflammatory cytokines or by 
knockout of IL-6 signalling. This activation of glia by opioids may be an 
explanation to “paradoxical“ opioid-induced pain enhancement, where 
prolonged opioid treatment leads to loss of antinociceptive efficacy, and also 
to decrease of nociceptive thresholds. In addition, glia may be an important 
factor in morphine dependence and withdrawal. In animal models, AV411 
(ibudilast), a blood-brain-barrier permeable glial activation inhibitor has 
prevented brain mediated withdrawal signs over time. Glial activation takes 
place in multiple sites along the pain pathway, including peripheral nerves, 
dorsal root ganglia and spinal cord. Study of the involvement of the brain glia 
in pain regulation is still in its infancy. It is already clear that glia in the brain 
regulates responses to opioids, such as morphine. There is evidence that glia in 
the medullary trigeminal ganglia regulates pain, and it seems likely that glia 
in the brain play an important regulatory role in pain enhancement, too.51, 143
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Figure 7. Classical and nonclassical views of pain transmission and pain modulation.  (a) 
Classical pain transmission pathway. Peripheral Aδ- and C-fibers respond to noxious 
stimulus. The axons relay action potential to dorsal horn, where the neurotransmitters 
of the sensory nerve are released, leading to activation of postsynaptic receptors 
on pain transmission neurons (PTNs). Axons of the PTNs then transmit information 
of the noxious event to the brain.  (b) Normal pain. Glia is quiescent, and does not 
release neuroexitatory subtances. Information of the noxiuos event is carried by 
Aδ- and C- fibers. Substance P and excitatory amino acids (EAAs) are released in 
amounts appropriate to stimulus intensity and duration. NK-1 and AMPA receptors are 
activated, and the generated action potentials are relayed to brain. (c) Pathological 
pain, classical view. In response to intense or prolonged pain, the PTNs become 
sensitized. The magnesium ions exit to NMDA-linked channel. This results in influx of 
calcium ions, and nitric oxide (NO) synthesis.  Presynaptically NO causes exaggerated 
release of substance P and EAAs, and postsynaptically PTN hyperexcitability. (d) 
Pathological pain, new view. Glial activation is considered as a driving force for 
creating and maintenance of pathological pain. Glia is activated (i) by bacteria and 
viruses which bind to specific receptors on microglia and astrocytes; (ii) by substance P, 
EAAs, fractalkine, and ATP, or by brain-to-spinal cord pain enhancement pathways; or 
(iii) by NO, prostaglandins (PGs) and fractalkine released by PTNs. Following activation, 
microglia and astrocytes cause PTN hyperexcitability and the exaggerated release 
of substance P and EAAs from presynaptic terminals. These changes are created by 
the glial release of NO, EAAs, reactive oxygen species (ROS), PGs, proinflammatory 
cytokines (IL-1, IL-6, and TNF), and nerve growth factor. The Figure is reprinted from 
Watkins LR and Maier SF. Immune regulation of central nervous system infections: from 
sickness response to pathological pain. Journal of Internal Medicine 2005;257:139-155 
with permission from the publisher.
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and postsynaptically PTN hyp rexcitability. (d) Pathological pain, new view. Glial activation is considered 
as a driving force for creating and maintenance of pathological pain. Glia is activated (i) by bacteria and 
viruses which bind to specific receptors on microglia and astrocytes; (ii) by substance P, EAAs, 
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inflammatory mediators (cytokines and chemokines) and pain
Cytokines are small regulatory proteins that are produced by white blood 
cells and a variety of other cells, including those in the nervous system. 
Cytokines act on hormonal concentrations through high-affinity receptors. 
They are produced upon demand and travel only short distances. Due to 
this local action, the serum levels do not necessarily reflect local activation. 
Cytokines have numerous effects on cells of the immune system and 
they modulate inflammatory mechanisms. Some cytokines are labelled 
pro-inflammatory, and the others anti-inflammatory. Three main pro-
inflammatory cytokines are interleukin-1β, interleukin-6 and tumor necrosis 
factor-α.123, 124 
Inflammation is a pathophysiological state associated with pain. The free 
nerve endings of peripheral nerve fibers in systemic tissues respond directly 
to inflammatory factors, such as lowered pH, bradykinin, histamine or 
prostaglandins, by generating electrical activity that is normally interpreted 
as painful. In models of inflammatory pain, pain is generally enhanced 
by pro-inflammatory cytokines and reduced by cytokine blockades. Pro-
inflammatory cytokines stimulate the production of the traditional chemicals 
of inflammation, such as prostaglandins.92   
Evidence has emerged that cytokines link the immune and the nervous 
system and that they may be involved in the generation of pain and 
hyperalgesia. The organisms’ response to infection is called the “illness 
response”, which is mediated via cytokines. The illness response is associated 
with fever, fatigue, loss of appetite, and hyperalgesia. During acute 
infections, hyperalgesia is one of the adaptive changes, which forces animals 
to decrease their use of energy.123, 146
Cytokines are produced by peripheral immune cells, and by CNS 
immunocompetent cells. In the CNS, glia is the predominant source of 
cytokines.145 In the peripheral nerve, axonal injury upregulates cytokine 
production.92, 123 Cytokine expression increases in human neuropathies such 
as chronic inflammatory polyneuropathy and Guillain-Barre syndrome.25 
Treatment of a neuropathic condition of erythema nodosum leprosum with 
thalidomide, reduced TNF-α secretion in peripheral blood mononuclear 
cells, and greatly reduced pain.13 Intravenous immunoglobulin reduced IL-1α 
and IL-1β levels in the plasma of patients with previously elevated levels, 
and reduced pain in a subgroup of patients. Models of painful nerve injury 
reveal changes in cytokine expression in the injured nerve itself, in the DRG, 
in the spinal cord dorsal horn, and in the CNS.54, 123, 131
Chemokines are a family of over 50 low molecular weight proteins, 
which are central to innate immune responses following tissue damage, 
injury and some diseases. They orchestrate the migration of leucocytes to 
inflamed tissues. Chemokines are divided to α-chemokines, β-chemokines, 
lympotactins and fractalkine. Synthesis of chemokines or receptor expression 
within the nervous system is linked to glial activation states and neuronal 
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hyperexitability, and has recently been implicated in the development and 
persistence of many pathological pain states. As an example is fractalkine, 
a factor released by neurons of the pain pathway. Fractalkine induces 
leucocyte migration and facilitates inflammation. Under normal conditions 
it is expressed on the extracellular surface of neurons, and fractalkine 
receptors are seen mostly on microglial cells. During pathological pain, 
fracatalkine receptor expression is increased in microglia, in pain-related 
areas. Application of exogenous fractalkine produces exaggerated pain 
responses by activating microglia and, on the other hand, intrathecal 
injection of fractalkine antagonist attenuates both thermal hyperalgesia 
and mechanical allodynia in experimental models of neuropathic pain.89, 151 
2.6. Examples of different neuropathic pain syndromes 
– different mechanisms
Peripheral neuropathic pain: small-fiber neuropathy
Small-fiber neuropathy is a subtype of sensory neuropathy, which exclusively 
or predominately affects small A-δ and C-fibers and their functions. Small 
somatic or autonomic fibers, or both, may also be involved. The most 
common aetiologies of small-fiber neuropathy are diabetes, followed 
by amyloidosis and Sjogren`s syndrome. The majority of small-fibre 
neuropathies remain idiopathic despite extensive evaluation. 
Most patients present symptoms between the age 45 and 70 years. 
Eighty percent of patients report burning pain in the feet. Pain, numbness, 
and paraesthesias occur in half of the patients. Reduced sensitivity to pin-
prick and temperature is almost always seen. Patients may also have loss of 
vibratory sensation at the toes or absent ankle reflexes. Nerve conducting 
studies are generally normal. 
Symptoms are usually distal, and “length-dependent”, starting from the 
feet. The hands often become affected over time. Symptoms restricted to 
upper limbs or cranial nerves are exceptional. A small number of patients 
develop more acute, diffuse or multifocal symptoms. These patients may 
slowly recover after a plateau, but symptom fluctuations may persist. In 
these cases, antecedent infectious illnesses have been reported.
Abnormal results in quantitative sensory testing (QST) have been 
reported in 60-85% of patients. However, QST has relatively low sensitivity 
and specificity. A more objective method is quantitation of intra-epidermal 
nerve fiber density. Reduced intra-epidermal nerve fiber density is observed 
in 50-88% of patients.6, 75, 94
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Lesion at the level of dorsal or cranial sensory nerve ganglia: 
Postherpetic neuralgia (PHn)
Herpes zoster is a neurocutaneus disease caused by reactivation of Varicella-
Zoster virus (VZV) from latency in dorsal or cranial sensory nerve ganglia. 
Herpes zoster predominately affects elderly people, and occurs as a result 
of ageing-related waning of cell-mediated immunity to VZV. In addition 
to the elderly, also immunocompromised patients are at risk to develop 
VZV reactivation. The most common complication of herpes zoster is PHN, 
persistence of pain for more than three months after the rash has healed. 
Like the zoster disease itself, the risk of postherpetic neuralgia increases 
with advancing age. The pain in PHN may be spontaneous, or stimulus-
evoked, and its intensity varies. Dynamic allodynia (pain in response to 
normally non-painful stimuli) is a typical clinical feature. The diagnosis of 
PHN is based on clinical history of herpes zoster, and typical sensory findings 
in clinical testings.34, 111, 149 
central neuropathic pain: central post stroke pain (cPsP)
Central pain is caused by a lesion in the brain or the spinal cord. In brain-
related central pain, approximately 90% of cases have vascular aetiology. 
CPSP is not a rare syndrome: 8% of stroke patients suffer from it, and in 
5% of them, pain is moderate to severe. CPSP is characterized by constant 
or intermittent pain occurring after stroke in those parts of the body which 
correspond to the cerebrovascular lesion. Hypersensitivity and sensory loss 
are typical features in clinical sensory examination.64 Most often CPSP is 
caused by a thalamic lesion, particularly within the ventroposterior inferior 
nucleus. Treatment of CSPS has remained as a challenge; the pain responds 
poorly to anti-analgesic drugs.7, 93
interaction of central and peripheral mechanisms and 
sympathetic nervous system: complex regional pain syndrome 
(crPs)
CRPS is a chronic neurological disorder characterized by disabling pain, 
swelling, vasomotor instability, sudomotor abnormality, and impairment 
of motor function. CRPS typically develops to an extremity after surgery 
or trauma. It may be divided into two subtypes depending on whether 
there is a nerve lesion present or not. Allodynia and hyperesthesia are 
often described as clinical features. The symptoms are not confined to the 
innervation zone of an individual nerve. It is probable that both peripheral 
and central mechanisms interact in the development of CRPS. Signs of 
inflammation with oedema and vasodilatation and increased cutaneous 
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temperature are often seen, therefore an inflammatory process in the 
periphery has been discussed. Changes within the pain-processing areas of 
the brain have frequently been reported in functional imaging studies.4, 61, 
62, 66
2.7. Herpes simplex viruses -1 and -2
Herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) are large double-
stranded DNA viruses of the Herpesviridae family. They share a 83% 
sequence homology of their protein-coding regions and the structure of 
their genomes is similar, but can be distinguished serologically.52 HSV-1 and 
-2 are among the most common human viral infections. They have been 
recognised since ancient Greeks, and because of their worldwide occurrence 
and ability to achieve a state of latency, they belong to the most harmful 
human pathogens. HSV-1, HSV-2, and VZV are neurotrophic, and classified 
as “alpha” herpes viruses.152
Transmission takes place usually through intimate contact, as HSV-2 
is transmitted predominantly sexually and HSV-1 mainly horizontally in 
childhood. HSV has no seasonal variation and it naturally infects only human 
beings. Most human beings have been infected and harbour latent virus 
that can reactivate, hence there is a vast HSV reservoir for transmission.100, 
109, 152
HSV enters the body through skin or mucosal surfaces, and it initiates 
cytolytic replication in epithelial cells at the entry site. Then it penetrates 
through the dermis and enters the ends of peripheral sensory nerves 
innervating the infected cells. The nucleocapside, containing the HSV DNA, 
is transported in a retrograde manner to the neuronal soma in the sensory 
root ganglia, where it converts to a latent state, and persists for the whole 
life of the infected person. Immune competence seems to be crucial for 
maintenance of latency, but the exact mechanisms of reactivation are 
unknown. Recurrence takes place, when HSV reactivates in sensory root 
ganglia, and is transported in the peripheral nerves back to the mucosal or 
skin surface. Recurrence may be triggered by physical or emotional stress, 
fever, ultraviolet light and tissue damage. Recurrences tend to be confined 
to the dermatome of primary infection but do not necessarily occur at 
precisely the same anatomic location. Reactivation of HSV becomes clinically 
evident only in a minority of patients.52, 119
Diagnosis of HSV can be confirmed by virus isolation in cell culture or 
PCR detection of HSV DNA.58 The development of type specific enzyme 
immunoassays (ELISA) that reliably distinguish between antibodies to HSV-1 
and HSV-2, enables serological studies which can measure both symptomatic 
and asymptomatic infections.100, 152
Clinical, epidemiological and biological properties in HSV-1 and HSV-2 
are different. Seroprevalence to HSV-1 varies from 52% (in Finland) to 84% 
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(in Czech Republic and Bulgaria), and to HSV-2 from 4% (in England and 
Wales) to 24% (in Bulgaria).100 
Antibodies to HSV-1 reduce the disease severity of HSV-2. Changes 
in seroepidemiology of HSV-1 and HSV-2 have been reported; the 
seroprevalence of HSV-1 has declined, while that of HSV-2 has increased in 
developed countries. Consequently, a greater proportion of HSV-2 infections 
will be primary (the patient is seronegative to HSV-1 when getting infected 
with the first HSV-2 infection), instead of initial (the patient is already HSV-1 
seropositive during the first HSV-2 episode). In primary HSV-2 infection, 
complications after the disease may be more frequent than in initial herpes 
infections.22
Historically, aciclovir has been used for treatment and suppression of 
various HSV-related conditions. Aciclovir is available in oral and intravenous 
formulation. Other effective antiviral agents for treatment and suppression 
of HSV include valaciclovir and famciclovir. They have a substantially higher 
bioavailability than aciclovir. Valaciclovir and famciclovir are available as oral 
preparations only.52, 152
clinical manifestations of HsV
HSV causes a range of diseases from mild uncomplicated mucocutaneous 
infections to life threatening ones. The severity of disease manifestations 
is dependent on a variety of viral and host factors. Patients with defects 
in cell-mediated immunity suffer from more frequent and more severe 
recurrences of HSV.109 
Gingivostomatitis is a symptomatic primary HSV-1 infection, usually 
occurring in children. After primary infection the virus remains latent usually 
in the trigeminal ganglia, and when reactivated, it causes facial herpes or 
cold sores. Symptomatic outbreaks of cold sores are estimated to affect 
20-40% of adults.119 More rare manifestations of HSV-1 in cranial region 
are ocular HSV-infections or herpetic facial paralysis. A serious neurological 
complication of HSV-1 infection is encephalitis which, if untreated, may 
cause death and in survivors permanent neurological defects, e.g. seizures, 
mental status changes, aphasia or motor deficit.49
HSV-2 causes predominantly genital herpes. Latency is established in the 
sacral root ganglia. One third of patients are estimated to have more than 
six recurrences per year, one third will have two recurrences per year and 
the remaining third only rare recurrences. Over time the recurrences will 
become less frequent. Transmission usually occurs from symptomless virus 
shedding.152 Neurological complications of HSV-2 include (recurrent) aseptic 
meningitis, myelitis and brainstem encephalitis. Radiculopathy caused by 
HSV-2 has been reported occasionally.53 HSV-2 encephalitis occurs mainly in 
newborn babies, and more rarely, in immunocompromised adults.49
Disseminated HSV-infections, with a progressive disease involving 
32 Review Of The Literature
respiratory tract, oesophagus, or gastrointestinal tract, are only seen 
in patients with an immunodeficient state, such as bone marrow 
transplantation, malignancy, malnutrition, alcoholism or pregnancy.109, 152
neuropathic pain and HsV
There is limited information about the association of neuropathic pain 
and HSV. Recurrent mucocutaneos HSV lesions are often preceded by 
pain, a burning or tingling sensation at the lesion site – the type of pain 
which resembles neuropathic pain. In acute phase of recurring HSV-2 
genital herpes, transient neuralgic symptoms may occur, but there are also 
case reports of chronic neuropathic pain in sacral area associated with 
the disease.53 HSV-2 induced radiculomyelitis may present clinically with 
neuralgic pain of the buttocks, perineum or legs, in addition to numbness, 
paraesthesias and urinary retention (Elsberg syndrome).109 In a one-year 
follow-up of patients with HSV-2 induced meningitis/meningomyelitis, 
chronic radicular pain, weakness, and paraesthesia of the lower limbs was 
reported.12 In addition, a painful syndrome of brachial neuritis (Parsonage- 
Turner Syndrome) has repeatedly been associated with viral infections, 
including HSV-1.71, 84
recurrent lymphocytic meningitis (rLm)
RLM was first described in 1944 by a French neurologist, Pierre Mollaret. 
Hence, the term “Mollaret meningitis” is frequently associated with this 
syndrome.116
RLM is a rare illness that manifests as recurrent episodes of aseptic 
meningitis. Symptoms during the meningitis episodes include fever and 
meningismus lasting for a few days, followed by spontaneous recovery. 
Symptomatic periods of the disease usually occur during 3 to 5 years.91 
There is a significant patient-to-patient variability regarding the time to 
recurrence, which may vary from weeks to years, and the total number of 
episodes, which may reach 30.18, 116 Women are affected more often than 
men, and the mean age of the patients is around 35-40 years.74, 130 Over time, 
recurrences become less common, although data from prospective studies 
that support this is limited.116
In 1991, Yamamoto et al. first reported a case of RLM attributed to 
herpes simplex virus; the viral DNA in CSF was detected by PCR. Since then, 
increasing evidence has accumulated that HSV-2 is the most common cause in 
RLM.104, 130 Almost 10% of patients may develop meningitis after the primary 
HSV-2 infection.20, 109 In patients with only a single episode of lymphocytic 
meningitis, enteroviruses are the most common etiologic agents.74, 76 
RLM may also be induced by autoimmune disorders, or medication, e.g. 
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nonsteroidal anti-inflammatory drugs, trimethoprim-sulfamethoxazole and 
intravenous immunoglobulin.60, 69, 76 
The clinical disease resolves spontaneously. Approximately one-half 
of the patients have transient neurological manifestations, including 
seizures, hallucinations, diplopia, cranial nerve palsies, or altered level of 
consciousness. Anecdotal evidence suggests that acyclovir, valacyclovir, 
and famciclovir, which have been administered to some patients for both 
episodic therapy and suppression of recurrences, might be beneficial, 
although there is no controlled trial data to support their efficacy and 
safety.116
The current diagnostic criteria state that RLM is a benign illness, and the 
patients should experience spontaneous recovery within a week.116 However, 
in addition to HSV recurrences, diffuse neurological complaints during the 
year following the acute phase have been reported in approximately one-
fourth of the patients.12
The characteristic cerebrospinal fluid (CSF) abnormality in RLM is 
lymphocytic pleosytosis. Protein levels in CSF are mildly elevated, and the 
glucose levels are usually normal. Analysis of CSF by PCR for HSV DNA is 
considered to be the gold standard for diagnosis.150 
In RLM probably all episodes are caused by the same etiologic agent. 
However, HSV-2 DNA is not always found in the CSF of the patients during 
a recurrence, despite an earlier HSV-2 DNA positive episode. Viral load and 
leucocyte counts reach significantly higher levels during the first episode 
compared with recurrent cases.40 False negatives may be caused by lower 
viral load in recurrences, which may also be due to earlier timing of the 
CSF sample.23, 135 
2.8. Immunology
The cells and molecules responsible for immunity constitute the immune 
system, and their collective and coordinated response to the introduction of 
foreign substances is called the immune response. The physiologic function 
of the immune system is defence against infectious microbes. However, even 
non-infectious substances, and mechanisms that normally protect individuals 
from infections and eliminate foreign substances, are capable of causing 
immune responses. 
Defence against microbes is mediated by early reactions of innate 
immunity and later responses of adaptive immunity. The innate immune 
response to microbes stimulates adaptive immune responses, and influences 
the nature of the adaptive responses. Adaptive immunity in turn, uses many 
of the effector mechanisms of innate immunity to eliminate microbes, and 
it also enhances the antimicrobial activities of the defence mechanisms of 
innate immunity.1
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innate immunity
Innate immunity is the immediate ability of the host to prevent and limit 
infections. It consists of cellular and biochemical defence mechanisms that 
are in place even before infection, and it provides rapid but incomplete 
host defence until the slower, more definitive, adaptive immune system 
is activated. Previous contact with an antigen is not needed.47 The innate 
immune system is phylogenetically older than the adaptive immune system. 
Innate immunity reacts only to microbes, and the response is essentially the 
same during repeated infections. Major participants of innate immunity 
are (i) physical and chemical barriers such as epithelia; (ii) phagocytic cells 
(neutrophils, macrophages) and NK cells; (iii) blood proteins including the 
complement system and other mediators of inflammation; and (iv) proteins 
called cytokines.1 Of these, the complement system is a key component, and 
plays a central role in host defence against pathogens.
Adaptive immunity
Adaptive immunity develops as a response to exposure to infectious agents. 
The response is increased in magnitude, and in its defensive capability with 
each exposure to a particular microbe. Characteristic for adaptive immunity 
are specificity for distinct molecules and an ability to “remember” and 
respond more vigorously to repeated exposures to the same molecule. 
Adaptive immunity is able to recognize and react to a large number of 
microbial and nonmicrobial substances. It has a capacity to distinguish even 
closely related microbes and molecules, and for this reason it is also called 
“specific immunity”. The components of adaptive immunity are lymphocytes 
and their products. There are two types of adaptive immune responses, 
called humoral immunity and cell-mediated immunity. 
Humoral immunity is mediated by molecules in the blood and mucosal 
secretions, called antibodies (immunoglobulins). They are glycoprotein 
molecules, produced by B lymphocytes that bind to antigens with high 
specificity and affinity. Antibodies recognise microbial antigens, neutralise 
the infectivity of the microbes, and target microbes for elimination by 
various effector mechanisms. The basic structural unit is an antibody 
composed of two identical heavy chains and two identical light chains. 
Every individual has millions of different antibodies, with unique binding 
sites. B lymphocyte is the only cell type capable of producing antibodies 
and therefore the central cellular component of humoral immunity. B cells 
develop in the bone marrow and mature cells are mainly seen in lymphoid 
follicles, in the bone marrow, and in low numbers in the circulation.
Cell-mediated immunity is mediated by T lymphocytes. T cells mature in 
the thymus, circulate in the blood, populate secondary lymphoidal tissues, 
and are recruited to peripheral sites of antigen exposure. Intracellular 
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microbes, such as viruses, survive and proliferate inside phagocytes and 
other host cells, where they are inaccessible to circulating antibodies. Cell-
mediated immunity is crucial in defence against such infections.1
immunoglobulin (ig)
There are five isotypes of antibodies, determined by which of the five 
different forms of heavy chains are present. These antibody isotypes include 
IgM, IgD, IgG, IgA, and IgE. Each isotype has different functions. IgA and 
IgG have additional structural variations.1 
immunoglobulin G (igG)
Human immunoglobulin G (IgG) can be subdivided into four subclasses: 
IgG1, IgG2, IgG3, and IgG4, each having unique biological and functional 
properties. IgG1 makes up most of the total IgG (66%), followed by IgG2, 
IgG3 (7%), and IgG4.99 Immunoglobulin G (IgG) subclasses IgG1 and IgG3 
mediate antibody-dependent cellular cytotoxity (ADCC) and are efficient 
activators of the classical complement pathway.87 Deficiency of IgG1 results 
in low levels in total IgG and is often, although not invariably, associated 
with susceptibility to bacterial infections. Deficiency of IgG3 is rather 
common. A clear clinical “phenotype” of IgG3 deficiency has not been 
defined, although susceptibility to viral infections, or prolonged clinical 
course of viral infections has been suggested.99 It is possible that isolated 
IgG3 deficiency is clinically relevant only in combination with other deficits 
(e.g. MBL deficiency). IgG1 and IgG3 deficiencies often occur together, 
and are thought to result from aberrant regulation of the expression of 
immunoglobulin heavy chain genes (IGH) encoding specific IgG allotypes.87
igG allotypes
Variations in IgG subclass levels are associated with Ig allotypes. Allotypes 
are genetic variants of Ig subclasses and light chains. Thirteen different IgG 
allotypes have been described; high and normal levels associated with (b) 
and (g) allotypes and low levels with the (g) allotype.99, 114 
the complement system
The complement system is a part of the innate immune system and also 
one of the major effector mechanisms in antibody-mediated immunity. It 
consists of more than 30 proteins in plasma and cell surfaces, and has three 
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physiologic activities: (i) defending against pyogenic bacterial infections, 
(ii) bridging innate and adaptive immunity, and (iii) disposing of immune 
complexes and the products of inflammatory injury. Recognition of the 
microbes by complement occurs through three distinct pathways: the 
alternative pathway (AP), the lectin pathway (LP) and the classical pathway 
(CP).139 All these pathways are activated in sequential manner, with the 
action of one component leading to the activation of the next one.
classical pathway
The classical pathway (CP) uses a plasma protein called C1 to detect IgM 
and IgG antibodies bound to microbe surfaces. Among the IgG subclasses, 
the IgG1 and IgG3 are the most efficient activators of the complement. 
Activation of the classical pathway is initiated by binding of the antigen-
antibody-complex to the C1 molecule. This induces a proteolytic cascade 
involving multiple complement proteins. In addition to the antigen-
antibody immunocomplex, various pathogens and molecules can bind to 
C1 and initiate the cascade. The classical pathway is an effector arm of the 
humoral immune system. It generates inflammatory mediators, opsonins 
for phagocytosis of antigens, and lytic complexes that destroy cells.1, 139, 140
complement protein c4 
Complement protein C4 (C4) is essential for the propagation of the 
classical and lectin pathways. It is the most polymorphic protein of the 
complement system. C4 has two isotypes, C4A and C4B, and is encoded 
by the closely linked C4A and C4B genes in the major histocompatibility 
complex (MHC) class III on chromosome 6. The plasma protein levels of 
C4A and C4B are mainly determined by the corresponding gene dosage. 
Deficiency or excessive amounts of C4 may affect an individual’s immune 
system. C4 deficiency may lead to defective processing of immune 
complexes, impairment of B cell memory, and persistence of bacterial and 
viral infections. Excessive amounts of C4 could possibly cause overactivation 
of the complement pathways and exacerbate the inflammatory response 
at local tissues.14
Lectin pathway
The lectin pathway (LP) is the most ancient pathway, triggered by a plasma 
protein called mannose-binding lectin (MBL). MBL bound to microbes 
activates one of the proteins of the classical pathway. The rest of this 
pathway is similar to the classical pathway.1
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mannose-binding lectin
Mannose-binding lectin (MBL) is a liver-derived plasma protein that 
activates the lectin pathway. It is a major pattern-recognition molecule 
of the innate immune system. It primarily recognizes sugar groups on the 
surfaces of microorganisms.32 It has been shown to bind to a wide range of 
pathogenic organisms including HSV-2.42 It is capable of promoting clearance 
of apoptotic cell debris and immune complexes from the circulation. 
The serum levels of MBL are determined by polymorphisms in the MBL2 
gene. Low serum concentrations of MBL are caused by point mutations in 
codons 52, 54, and 57, in exon 1 of the MBL2 gene. The concentration is 
also dependent upon several promoter region polymorphisms of the gene.82 
Approximately 5% of the Finnish population have MBL deficiency, defined 
as an undetectable level of MBL in the serum. A large proportion of these 
individuals are asymptomatic.3 
The clinical relevance of MBL deficiency is controversial. In some studies 
MBL deficient patients seem to be prone to severe diseases caused by 
encapsulated bacteria, and to illnesses caused by a broad range of viruses, 
fungi, and parasites. However, many of these associations are weak, or 
contradictory. In most cases, other components of the immune system can 
compensate for the lack of MBL. It is possible that MBL deficiency becomes 
clinically manifest only when it occurs in association with some other form 
of immunodeficiency.3 
On the other hand, high frequencies of variant alleles in certain 
populations suggests that MBL deficiency may also be advantageous. 
Some intracellular pathogens use C3 opsonization to enter their host. Any 
reduction in complement-activating function may reduce the probability 
of parasitization. Hence, MBL deficiency may protect against parasitic 
infections (e.g. malaria).32
MBL deficiency may have an impact on protective immunity at the 
population level, as susceptibility to many common infectious diseases is 
under complex genetic control.17
major Histocompatibility complex (mHc)
MHC was first discovered as a genetic locus containing highly polymorphic 
genes that determined the outcome of transplants exchanged between 
individuals. Now it is known that the MHC region takes part in innate 
and adaptive immunity. The physiological function of MHC molecules is 
the presentation of microbial peptides to the appropriate subset of T cells 
(adaptive immunity). Human MHC molecules are called human leucocyte 
antigens (HLA).1 
MHC genes are the most polymorphic genes present in the genome. For 
some HLA loci, more than 250 alleles have been identified by serological 
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assays, and molecular sequencing has showed even greater polymorphism 
than predicted by serologic studies. The set of MHC alleles present in one 
chromosome is called the MHC haplotype. An individual’s response to 
infections and inflammatory insults is affected by inherited haplotypes. Both 
disease-predisposing and protective HLA haplotypes, and alleles associated 
with various rheumatic and infectious diseases have been reported.16
There are two main types of MHC gene products, called class I and 
class II MHC molecules. The classical class I loci, HLA-A, -B, and -C, encode 
molecules that bind antigens usually derived from the intracellular 
pathogens and present them to CD8+ T cells, thereby initiating a cytotoxic 
T cell response. The classical class II loci, HLA-DR, -DQ, and -DP, specify 
molecules that primary bind peptides of extracellular origin and present 
them to CD4+ T cells, resulting in cytokine production and T cell help in 
antibody production.1
The MHC region encodes at least 240 genes, of which about 130 are 
considered to be functional (Figure 8). Of these, at least 40% are involved 
in immune response.16 A high diversity is crucial to defence against micro-
organisms. MHC genes have been associated with more than 100 diseases, 
including common diseases, such as diabetes, rheumatoid arthritis, 
psoriasis, asthma and various autoimmune disorders. Identification of 
these associations is complicated by the strong linkage disequilibrium 
that exists between the HLA genes and by environmental factors such as 
infectious agents and allergens.118 Conclusive association studies regarding 
the influence of HLA on infectious diseases require large samples, proper 
ethnic-background stratification, accurate clinical information, and use of 
models that consider other known genetic effects on the disease. Fulfilling 
these criteria is difficult.16
Despite this, a number of convincing HLA class I and class II associations 
with infectious diseases have been identified.  Previously, HLA-DRB1*01 
has been associated with periodontal pathogens in Finnish coronary artery 
disease patients, as and HLA-B*27 and HLA-B*35 with infectious or post-
infectious complications in chronic herpes simplex virus infections, HIV, 
reactive arthritis and Chlamydia pneumoniae infections.16, 77, 96, 97, 120
The haplotype HLA-A*3303-B*4403-DRB1*1302 has been shown to 
predispose to neuralgia after herpes zoster in Japanese patients.110
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Figure 8. Gene map of the HLA region. The regions separated by arrows show the 
HLA sub-regions, such as classical class I-III regions. White, grey, striped and black 
boxes show expressed genes, gene candidates, non-coding genes and pseudogenes, 
respectively. The Figure reprinted from Shiina T et al. An update of the HLA genomic 
region, locus information and disease associations. Tissue Antigens 2004;64:631-649 
with permission from the publisher.
2.9. Methods of evaluating the pain pathway
Peripheral level
Pain is a complex physiological and clinical phenomenon characterized by 
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subjective sensory qualities, such as its time of onset or specific location 
on the body. Strong affective reactions associated to pain heighten its 
complexity. Despite these challenges, the patients are able to provide 
reliable information of their pain experience on structured physiological 
testing. The evaluation of the functional status of the nervous system that 
conveys pain information is based on the subjects` ability to report and 
quantify their pain experience. The perception of pain depends on activation 
of specific peripheral nerve fibers and their central connections.68 C- and 
Aδ-fibers mediate pain, and damage to them or their central connections 
underlie all neuropathic pain.94 
Diagnosis of neuropathic pain is often possible in clinical bed-side 
examination. Location and quality of pain may be determined, pain intensity 
may be assessed by using visual analogue scale (VAS), and sensory symptoms 
may be evaluated by simple equipment: a piece of cotton wool, wooden 
cocktail stick, warm and cold objects and a tuning fork. Nerve conduction 
studies and somatosensory-evoked potential, which do not assess small fiber 
function, may demonstrate and localize a peripheral or central nerve lesion. 
Quantitative assessment of Aδ- and C-fibers is possible by using quantitative 
sensory testing, laser-evoked potentials (LEPs), and skin biopsy. The LEPs are 
an easy and reliable method of assessing function of nociceptive pathway, 
but in clinical practice they are available in few centres only.21
Quantitative sensory testing (Qst)
In the peripheral nervous system, pain is mediated by myelinated Aδ- and 
non-myelinated C-fibers. Cold perception and the first (sharp and localized) 
pain are mediated by the relatively fast (5-30 m/s) conducting Aδ-fibers 
and warm perception and the second (dull) pain by the slow conducting 
(1-2.5m/s) C-fibers.107 
Determination of the thermal perception thresholds is an established 
method for the study of small nerve fiber function. Commonly used 
measurements are the reaction-time-inclusive method of limits and the 
reaction-time-exclusive method of levels; of these the method of limits 
is most commonly used because it is easy and fast to use. In the method 
of limits, the stimulus temperature increases or decreases with constant 
rate, starting from the temperature of +32 °C. When the patient gets the 
sensation of warm or cold, or heat or cold pain, he pushes a button, after 
which the temperature returns to 32°C. In this method, the subjects` state 
of alertness and motivation influence the results.107
Patients with neuropathic pain may have negative sensory phenomena, 
for example thermal sensory deficits, where thermal innocuous and pain 
thresholds are elevated. They may also have positive sensory phenomena 
(hyperalgesia and hyperesthesia), where the thermal pain thresholds are 
lowered. Both these abnormal states can be measured with QST. 
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One limitation of the method has been the lack of comprehensive 
normative data. The perception thresholds may vary according to the 
specific body area, and in some studies according to age and gender.68 Age-
related differences appear to be most prominent with patients above the 
age 60 years. Thermal sensation and heat pain thresholds may also slightly 
vary when same subjects are measured repeatedly.98 Instead, there are no 
significant differences in QST-parameters observed between the right and 
left sides of the body.108
There is greater variability of noxious thresholds than innocuous 
thresholds.  Pain is strongly influenced by individual modulatory mechanisms, 
at the spinal cord, brainstem, thalamic and cerebral levels of the pain-
pathway, which cannot be controlled by measurement protocols. Cold pain 
is the most susceptible modality in this regard.68
skin biopsy
Intraepidermal nerve fiber density (IENF) quantitation is established as 
a diagnostic and research tool for conditions affecting unmyelinated 
C- and Aδ-fibers, such as idiopathic painfull small-fiber neuropathy, 
diabetic neuropathy, HIV neuropathy, and Fabry´s disease. This method 
is quantitative, it can be used for serial testing, the skin biopsies are 
easy to perform, and the method has high sensitivity and specificity. In 
different studies slightly variable techniques are used. Usually 3 mm punch 
biopsies are taken under local anaesthesia at the ankle, 10 cm above lateral 
malleolus. The biopsy specimens are fixed, frozen or embedded in paraffin, 
cut into 10-100 μm thick sections, and immunostained for the panaxonal 
marker, PGP 9.5. The nerve fibers are counted by laser scanning confocal 
microscopy or light microscopy.70, 75, 137 Some of the methods are methodically 
demanding, which is why the acceptance of the method for wider use has 
been relatively slow. Counting the nerve density per epidermal area by light 
microscopy after immunohistochemical staining may prove to be easier.70 
Controversial results exist concerning the influence of age, gender, 
and anthropometric variabiles on IENF density in normal individuals. Most 
studies have reported a reduction of IENF density with increasing age. 
The influence of gender, height, and weight are controversial. There are 
reports suggesting that women have greater epidermal nerve fiber density 
than men.50 Most studies have shown a length-dependent pattern of IENF 
density in normal individuals: IENF density at the distal thigh is about 60% 
higher than at the distal leg segment.137 No correlation with the duration 
of diabetes or level of glycemic control with IENF density was obsereved.136 
There is limited longitudinal information on patients undergoing serial 
biopsies. In a small study of patients with sensory complaints of the feet, the 
swelling of large nerve fibers in the initial biopsy, correlated to a decline in 
IENF density in repeated biopsies.48 In patients with CRPS, IENF density was 
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diminished at the site affected by CRPS, but not in the ipsilateral unaffected 
control site, or contralateral matching control site.94
Functional brain imaging in pain
Current functional neuroimaging methods for human brain mapping in pain 
are based on two different principles: measuring of either hemodynamic 
or electrophysiological changes (Figure 9). Available methods based on 
hemodynamic principles are functional magnetic resonance imaging 
(fMRI), positron emission tomography (PET), single-photon emission 
computed tomography (SPECT) and near-infrared spectroscopy (NIRS). 
Electrophysiological techniques include electroencephalography (EEG), 
magnetoencephalography (MEG), and transcranial magnetic stimulation 
(TMS). Hemodynamic methods are superior in spatial resolution, compared 
to electrophysiological methods, which have a theoretical advantage of 
detecting cortical activities within a millisecond’s resolution (Table 1).67, 117
The first human brain imaging studies using modern technologies were 
published in early 1990s. Those studies indicated that multiple cortical and 
subcortical regions are activated during painful cutaneous heat stimuli in 
healthy subjects.
Figure 9. Brain imaging techniques used in the study of pain. MEG and EEG provide the 
most direct measures of neuronal activity, whereas PET and fMRI measure an indirect 
hemodynamic response. The Figure is reprinted from Kupers R and Kehlet H. Brain 
imaging of clinical pain states: a critical review and strategies for future studies. The 
Lancet Neurology 2006;5:1033-1044 with permission from the publisher.
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Temporal
resolution
Spatial
resolution Advantages Disadvantages
PET >40 s >4 mm
Measures activity in cortical and
subcortical structures.
Stimulus independent 
technique.
Allows receptor binding 
studies.
Radioactivity.
Poor temporal resolution.
Invasive technique.
Limited amount of scans
possible.
fMRI 100 ms-3 s >2 mm
Measures activity in cortical and
subcortical structures.
Excellent spatial resolution.
Poor patient comfort.
Requires non-magnetic
equipment.
Stimulus-dependent
technique.
MEG milliseconds >2 mm
Excellent temporal resolution.
High patient comfort.
Ecological method.
Difficulties to measure
subcortical activity.
Requires non-magnetic
equipment.
Stimulus-dependent
technique.
Table 1. Characteristics of different brain imaging techniques used in the study of 
pain. The Table is reprinted from Kupers R and Kehlet H. Brain imaging of clinical 
pain states: a critical review and strategies for future studies. The Lancet Neurology 
2006;5:1033-1044 with permission from the publisher.
Functional magnetic resonance imaging (fmri)
fMRI imaging is a powerful tool for imaging functionally active brain regions 
in health and diseases. The most common method is blood oxygenation 
level-dependent (BOLD) imaging. fMRI BOLD imaging is based on the 
magnetization difference between oxyhemoglobin and deoxyhemoglobin, 
which constitutes a measure of haemodynamic response. The BOLD contrast 
is thought to reflect the population synaptic activity of given brain regions. 
In the area of brain where a neuronal group is activated, the concentration 
of deoxyhemoglobin is relatively decreased, and that area can be visualized 
as high signal intensity on T2-weighted image.117
Both primary somatosensory cortex (SI) and secondary somatosensory 
(SII) cortex are commonly activated in heat pain studies. Evidence suggests 
that nociceptive input to these regions at least partially underlies the 
perception of sensory features of pain. Anterior cingulate (ACC) and insular 
cortices (IC), both components of the limbic system, are activated during 
the majority of PET and fMRI studies of heat pain. These regions have been 
implicated in the affective processing of pain. Prefrontal cortical areas, as 
well as parietal association areas, are also sometimes activated by heat 
pain and may be related to cognitive variables, such as memory or stimulus 
evaluation. Subcortical activation is also seen, most commonly in thalamus, 
basal ganglia, and cerebellum.8
fMRI of pain has produced results that are in agreement with prior 
reports using PET. It has revealed novel regions of the brain involved in pain 
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processing. High-resolution fMRI has allowed the imaging of the brainstem 
in human subjects exposed to noxious stimuli, and measurement of neuronal 
activity in the spinal cord in both healthy and injured subjects. fMRI also 
demonstrates that the magnitude of the fMRI signal reflects the perceived 
intensity of pain.126 Experimental studies suggest that hemodynamic 
response is significantly correlated to neuronal activity, especially synaptic 
activity. However, the hemodynamic response tends to be more widespread 
in space and lasts longer in time as compared with neuronal activity.117
Different types of pain have been associated with different patterns 
of brain activation, for example thermal and mechanical hyperalgesia 
produce substantially different brain activation patterns.126 There may be 
sub-regional differences in the processing of different types of pain. In 
several studies, ACC has been divided into different components, proposing 
different responses to different stimuli. Further, it has been suggested that 
affective reactions to pain would be localized to rostral ACC, while cognitive 
processes to the mid-cingulate region.8 
The processing of painful stimuli in the brain always involves psychological 
modulation of pain. Studies examining the effects of distraction show pain-
evoked activity in SI, ACC, IC, and thalamus. Other regions, including PAG, 
parts of ACC, and the orbitofrontal cortex are activated when subjects are 
distracted from pain, suggesting that these regions may be involved in the 
modulatory circuitry related to attention. Emotional state can influence pain 
perception, and negative emotional states enhance pain evoked activity in 
limbic regions, such as ACC and IC. The anticipation of pain can activate 
pain-related areas such as SI, ACC, PAG, IC, PFC and cerebellum, in the 
absence of physical pain stimulus.133
fmri (and other hemodynamic methods) in clinical pain 
It is probable that different clinical pain states generate different brain 
activation patterns. In clinical pain studies reported, the patient populations 
studied vary greatly in terms of the aetiology of pain, duration of pain, 
localisation of pain, type of pain, distribution of pain and psychological 
factors. All these differences make interpretation of the results challenging.
It is diffucult to find patients with pain in the same anatomical region. 
Differences in pain afflicted areas may affect to activation patterns in 
regions with known pain-related somatotopic organization.73 Varying 
duration of pain may affect the results: in one study, hyperperfusion of the 
contralateral thalamus was observed in CRPS patients, if the duration of 
pain was only 3 to 7 months, whereas in long-term pain, hypoperfusion of 
the same area was observed.41 
Supraspinal activation patterns for acute pain in healthy subjects differ 
from those seen in clinical pain conditions. When attempting to study 
clinical pain states with hemodynamic methods, the earliest approach was 
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application of similar painful stimuli to healthy subjects and patients with 
different pain states. In those studies, when compared to healthy controls, 
patient brain activity to thermal stimuli was reported to be decreased in 
rheumatoid arthritis, in patients with atypical facial pain, and in patients 
with post-tooth extraction pain.27, 65 Those early studies had several 
methodological weaknesses. Later, low back pain patients compared to 
matched normal controls showed no significant changes to responses to 
thermal stimuli applied to the hand.26 
In neuropathic pain, a number of studies have investigated cerebral 
responses to stimulation of allodynic areas in a nerve-injured territory, and 
compared it to the healthy, contralateral side. Peyron et. al. found that 
responses to allodynic stimuli were enhanced in the hemisphere ipsilateral 
to allodynia, whereas in the contralateral hemisphere, there was a complex 
pattern of response attenuation (SII and insula) and enhancement (ACC, 
sensorimotor and posterior parietal cortices).103 Hypoesthetic skin areas have 
rarely been studied, and it is likely that responses to stimulation of allodynic 
and hypoesthetic skin areas produce different brain activation patterns.
Increases in cerebral blood flow in the ACC have been reported 
in psychiatric patients with obsessive-compulsive disorders, anxiety, 
post-traumatic stress or mood disorders like depression.102 Anxiety and 
depression are likely to be present also in chronic pain, thus affecting the 
pain experience and making the interpretion of observed hemodynamic 
changes difficult.
In some clinical pain states it is possible to provoke the pain and measure 
the underlying brain activity. For example, in patients with migraine with 
aura, there is a decrease observed in blood flow and activity in occipital 
area, during a migraine attack.83, 148 In a few reports, ongoing neuropathic 
pain has been alleviated by anaesthetic blocs or central pain has been 
treated with motor cortex stimulation.45, 57 However, in most pain conditions, 
including neuropathic pain, manipulation of ongoing pain is not possible. In 
those conditions application of equated stimuli (equalization of percepted 
intensity of pain in VAS-scale) between the patients and normal controls 
has been used in several studies.8
Responses to painful stimuli may be activation or deactivation of pain-
related areas. In healthy subjects the response to painful stimuli is often 
increased activity in those areas. In clinical pain, however, deactivation and 
attenuated responses have been reported. Attenuation of cortical responses 
has also been considered as a sign of possible lesion in spinothalamic tract.43
Contralateral thalamus is activated in response to pain in healthy 
subjects. Thalamic activation may also be bilateral, which suggests that 
thalamic activation in pain may reflect arousal reaction to pain. In contrast 
to experimental pain in normal controls, chronic pain is often associated 
with decreased activity in the contralateral thalamus. This deactivation 
may be reverted by analgesic procedures.102 In normal subjects the stimulus 
is transmitted via the spinothalamic pathway through the thalamus to SI, 
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SII, IC and ACC. It has been suggested that in chronic pain, the activity of 
this pathway decreases, and the PFC activity seems to increase, indicating 
that pathways outside the spinothalamic tract, such as spinoparabrachial, 
spinohypothalamic, and spinoreticular projections, may become more 
important in chronic pain.8 It has also been thought that the hypofunctional 
thalamus does not allow for adequate descending inhibition during chronic 
pain states.5
In a meta-analysis of several studies on clinical pain states it was 
concluded that chronic clinical pain conditions more frequently involve 
PFC, while experimental pain involves SI, SII, thalamus and ACC. The stronger 
activation of PFC suggests that chronic pain has stronger emotional and 
cognitive components than experimental pain.8 
Voxel-based morphometry (VBm)
Voxel-based morphometry involves a voxel-wise comparison of the local 
concentration of gray matter between two groups of subjects. There is 
a number of morphometric features that may be difficult to quantify by 
inspection, meaning that many structural differences may be overlooked. 
VBM is not biased to one particular structure and it gives a comprehensive 
assessment of anatomical differences throughout the brain. VBM deals 
with differences in the local composition of brain tissue after macroscopic 
differences in shape have been excluded. The procedure involves spatially 
normalizing images from all subjects in the study into the same stereotactic 
space. This is followed by segmenting and smoothing of the gray-matter 
segments. Statistical methods are used to compare the two groups.11
Voxel-based morphometry in clinical pain
Voxel-based morphometry has demonstrated a significant reduction in gray 
matter volume of the dorsolateral prefrontal cortex and the right thalamus 
in patients with chronic back pain. The magnitude of the decrease was 
equivalent to the loss of gray matter volume during 10 to 20 years of normal 
ageing. There was also a correlation between the loss of brain volume and 
duration of pain.9 The gray matter volume was reduced in the brains of 
fibromyalgia patients, especially in the posterior cingulate gyrus, left IC, 
and the medial frontal cortex.72
The observed atrophy was distinct from that described in chronic 
depression, anxiety, or neurodegenerative conditions such as Alzheimer´s 
disease. Common pathological hallmarks of neurodegeneration and pain 
include inflammation, glial activation, and apoptosis. This shared pathology 
may explain the atrophy in seen pain patients, although it is not clear how 
universal this finding is in different pain states.9
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magnetoencephalography (meG)
Magnetoencephalography is a non-invasive method, where magnetic 
fields are measured outside the skull. The magnetic fields are generated 
by simultaneously firing neurons. The skull, scalp, and brain do not 
distort magnetic fields, so the cortical activity can be easily measured.55 
The following four areas are constantly activated in experimental pain in 
healthy subjects in MEG: (i) primary somatosensory cortex (SI) contralateral 
to the stimulated side, (ii) secondary somatosensory cortex (SII) in the 
bilateral hemispheres, (iii) insula in the bilateral hemispheres, and (iv) 
cingulated cortex in the bilateral hemispheres.67 Very few EEG or MEG 
studies demonstrate activity in IC and neither method shows activation 
of the thalamus or PFC. IC and the thalamus may be missed because of 
their position deep inside the brain, since location accuracy of both these 
techniques decreases with increasing distance from the scalp.8  Compared 
with hemodynamic imaging studies, magnetic recordings are highly 
sensitive to describe activity in the SII region. MEG is more sensitive than 
EEG in recording the sources in SI and SII, which are oriented tangentially 
to the scalp. Radially oriented current flow in ACC activity is more 
frequently detected in EEG.8 The temporal resolution of MEG is superior 
to hemodynamic methods. The sensation of pain elicted by a brief painful 
stimulus is reflected in two sequential brain activations in MEG recordings 
from SI, SII and ACC. This is due to different conduction velocities in 
nociceptive Aδ- and C-fibers.8 Different sensory stimuli can be used during 
the measurements. Tactile stimuli can be delivered to fingertips with 
diaphragms driven by compressed air. A painful stimulus which selectively 
stimulates nociceptive Aδ-fibers may be delivered by laser beam. A selective 
stimulation of C-fibers is possible by decreasing the total energy of a laser 
beam and by restricting the size of the stimulated skin area. The activity 
generated by these methods is termed as laser evoked potential (LEP).67
meG in clinical pain
Bodily representations of the SI cortex vary according to sensory input. 
Excessive training may lead to an increase in cortical representation areas 
of the fingers.35 On the contrary, loss of sensory input, e.g. after amputation 
of the arm, leads to changes in cortical representations, and the amount 
of cortical reorganizations correlates with the magnitude of phantom-limb 
pain.39 Hence, in amputation patients, the changes may be due to both 
deafferentation, and the pain. However, cortical reorganization also occurs, 
when there is no loss of peripheral input to brain, indicating that pain 
itself may be associated with reorganization of the primary somatosensory 
cortex. In patients with CRPS type I (when there is no evident lesion of 
afferent nerves), the distance between the thumb (D1) and little finger (D5) 
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representation areas decreased in distance, and the representation areas 
shifted to more lateral and inferior position toward the lip.66, 80 Changes also 
correlated with pain intensity and the presence of mechanical allodynia. 
During healing process, a reduction of CRPS pain correlated with recovery 
from cortical reorganization. Reorganization of SI cortex has also been 
reported in low back pain patients. In MEG measurements, the amplitude 
of the response depends on the number and synchrony of the activated 
neurons. In CRPS, the stronger SI activation to tactile stimulation of the 
painful than to the non-painful hand has been suggested to reflect central 
sensitization, as these patients have allodynia and hyperesthesia in the 
affected limb.38, 66, 80, 81 In addition to CRPS and phantom-limb pain, there are 
only few other clinical pain conditions examined by MEG, including small 
studies of low-back pain and carpal tunnel syndrome.38, 129
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3. Aims Of The Study
The aims of the study were to characterize two subgroups of patients with 
a HSV-associated clinical condition. The specific objectives of this Thesis 
were the following:
1. To characterise the clinical picture, immunological features and changes 
in brain morphology and function in patients with widespread unilateral 
pain and HSV-infections (I, II). 
2. To analyse the prevalence, clinical symptoms and immunological 
predisposing factors of HSV-2 induced RLM in the southern part of 
Finland (III, IV).
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4. Subjects And Methods
Widespread unilateral pain
Patients: Twenty-two patients with widespread unilateral pain covering a 
large area of the body during the time period of 12/2002 and 1/2004, were 
evaluated for the study. The patients were recruited from the Pain Clinic and 
from the Division of Infectious Diseases of the Helsinki University Central 
Hospital. In addition to infectious problems, the patients had severe pain 
which had spread outside the original territory but remained on one side 
of the body (inclusion criteria: the painful area covered face or trunk or 
both, and one or two extremities). As the majority (n=17) of patients had 
recurring HSV-1 and HSV-2 infections, we decided to study the role of HSV-1 
and -2 infections in the pain condition. A subgroup of patients (n=8), with 
the most widespread clinical pain and hypoesthesia as a clinical sensory 
finding were also recruited to a fMRI study.
Controls: For laboratory analyses (except for the frequencies of the HLA 
alleles), 51 age- and sex-matched controls (regardless of seropositivity or 
negativity to HSV-1 or HSV-2) were selected from a population of 150 
consecutive voluntary subjects who visited the Vita Laboratories Ltd (Helsinki, 
Finland) for health survey before accepting a new job. An additional 
statistical analysis was made by using 34 age- and sex-matched, HSV-1 or 
HSV-2 seropositive controls also selected from the original 150 subjects. By 
two controls groups we tried to assess whether the immunological profiles 
potentially predisposed to complicated HSV infections or to neuropathic 
pain. For the frequencies of the HLA alleles, 90 Finns were used as historical 
controls (population matched historical control material available in: 
http://www.ncbi.nlm.nih.gov/gv/mhc/main.fcgi?cmd=init IHWG projects-
Anthropology/ Allele frequencies -Select population -Finn90). A control 
group for VBM comprised 28 healthy adults (18 females, 10 males, mean 
age 32). Of these, eleven subjects (5 females, 6 males, 10 right-handed, 
mean age 30) served as controls also for the fMRI. These controls were not 
age- nor sex –matched.
Clinical examination: A questionnaire designed for this study (including 
questions about general symptoms, infectious diseases, musculoskeletal 
and neuropathic pain, and treatments) was used to interview the patients. 
Neurological examination (evaluation of the brainstem function, balance, 
coordination, muscle strengh, tendon reflexes, cognition, fine motor skills, 
sensory evaluation) was performed. Evaluation of sensory function included 
responses to pressure, pin-prick, cotton-wool, cold and warm objects in 
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painful and non-painful skin areas.
Quantitative sensory testing (QST) (Medoc TSA II; Medoc, Ramat Yishai, 
Israel) was performed at normal room temperature on four sites; two on 
the painful area of the body, and for reference, two on the corresponding 
contralateral side of the body. The method of limits was used to determine 
thresholds for warm and cold detection, and for heat and cold pain. The 
time between different stimuli was 60 seconds, or - in case of hyperpathy - 
until the sensation had passed. When cold (skin temperature under +31°C), 
the hands were warmed under warm water. In addition, in patients recruited 
to a fMRI study, the current pain intensity was evaluated with VAS-scale, 
and tactile sensitivity and two-point discrimination on the hands was tested 
with monofilaments (Touch-Test Sensory Evaluator, North Coast Medical, 
Morgan Hill, CA). 
Laboratory tests: Plasma concentrations of IgG, IgA, IgM (Dade Behring 
BN Prospec, Deerfield, IL) and IgG subclasses (Ig1-4) (Peli-Class BN, Sanguin 
Reagents, Amsterdam, The Netherlands), and serum concentrations of C3 
and C4 (Behringswerke AG, Marburg/Lahn, Germany) were measured by 
nephelometry. Serum classical pathway haemolytic activity was determined 
by an enzyme-linked immunosorbent assay technique (CH50; Quidel 
Corporation, San Diego, CA).The Manufacturers´ reference values for levels 
below two standard deviations from the mean were used to define low 
levels (=values below two standard deviations from the mean). The cut-
off values were 6.8 g/l for IgG, 0.88 g/l (males) and 0.52 g/l (females) for 
IgA, 0.36 g/l (males) and 0.47 g/l (females) for IgM, 4.9 g/l for IgG1, 1.5 
g/l for IgG2, 0.2 g/l for IgG3, 0.08 g/l for IgG4, 0.71 g/l for C3, and 0.12 
g/l for C4. Type-specific HSV-1 and HSV-2 antibodies were measured by 
commercial EIAs according to the Manufacturers´ instructions (HerpeSelect 
1 & 2 IgG; Focus Diagnostics, Cypress, CA; EIAgen HSV IgM, Adaltis, Bologna, 
Italy). Complement C4 allotypes were determined electrophoretically. The 
absence of an isotype was confirmed by isotype-specific PCR amplification 
of the C4A and C4B genes. DNA samples were genotyped for HLA-A, HLA-
B, and HLA-DRB1 by means of commercial kits from Biotest (ABDR SSP), 
Dreieich, Germany, or One Labda (ABDR SSP), Canoga Park, CA; with low 
to intermediate allele resolutions. In a subgroup of 12 patients, also IgG1 
and IgG3 allotyping (Gm) was performed: allotypic markes of IgG1 were 
detected with double diffusion precipitation in gel (IsoGel Agarose, FMC 
BioProducts, Rockland, ME), and allotyping for IgG3 was obtained as a 
by-product of their quantitation with inhibition ELISA. 
Skin biopsies: As a pilot study, skin biopsies were taken from six patients. 
The biopsies were taken 10 cm above the lateral malleolus from both sides. 
In all patients, one biopsy was taken from the painful area, and could be 
compared with the one taken from the corresponding contralateral non-
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painful area. The samples were fixed in 10% formalin, after which they 
were embedded in paraffin. Thin 10 µm sections were cut and stained with 
polyclonal gene product (PGP) 9.5 (Ultraclone, Isle of Wright, UK). Using 
light microscopy, immunopositive intraepidermal nerve fibers were counted 
per epidermal area.
Functional magnetic resonance imaging: During fMRI measurement, thermal 
stimuli to the right and left hand dorsa were delivered via 16 mm x 16 mm 
Peltier thermodes of the TSA II devices, and tactile stimuli to the index, 
middle and ring fingers via diaphragms driven by compressed air. fMRI was 
performed with a 3.0 T Signa Excite scanner (General Electric, Milwaukee, 
WI) using a gradient-echo (GRE) echo planar imaging (EPI) sequence. 
Imaging the whole brain required 31 oblique slices, each 4 mm thick. The 
tactile stimulation series was conducted first and the pain stimulation 
series immediately afterwards. The subjects were instructed to lie still and 
keep their eyes open during the imaging. High resolution T1-weighted 
anatomical images were acquired during the same MRI session. The fMRI 
data was preprocessed with BrainVoyager QX (Brain Innovation, Maastricht, 
The Netherlands). Both functional and anatomical images were normalized 
to Talairach space for subsequent analysis. The data of the patients with 
pain in the left side of the body (n=4) were mirrored across the midsagittal 
plane. In group comparison half of the controls were mirrored in the same 
manner, to minimize the possible effects of unsymmetrical activations to 
left- and right-hand stimuli. In VBM, T1-weighted anatomical images were 
obtained, and further preprocessing of the data was conducted according 
to the optimized VBM protocol with software package SPM2 (Wellcome 
Department of Imaging Neuroscience, London, UK).
recurrent lymphocytic meningitis
Patients: All patients in Helsinki and Uusimaa Hospital District area (a total 
population of 1.4 million) with a recurrent HSV-2 lymphocytic meningitis 
(defined as two or more clinical episodes of lymphocytic meningitis, and 
HSV-2 DNA in at least one CSF sample) between January 1994 and December 
2003, and willing to take part in the study, were recruited to the patient 
study (n=22). Of these, 21 patients went further to laboratory analysis (one 
patient had to be excluded due to a clinical condition, which probably 
affects on immunological analyses). For prevalence study, all patients 
diagnosed with RLM (n=37) between January 1996 and December 2006 
were included. 
Controls: For laboratory analyses (except for the frequencies of the HLA 
alleles), 62 age- and sex-matched healthy subjects were selected from a 
population of 150 matched consecutive voluntary subjects who visited the 
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Vita Laboratories Ltd (Helsinki, Finland) for health survey before accepting 
a job, to serve as controls. For the frequencies of the HLA alleles, 90 Finns 
were used as historical controls.
Prevalence study: The Helsinki and Uusimaa Hospital District Database of 
ICD-10 diagnostic codes A87, B00.3+G02.0, B01.0+G02.0, B02.1, G02*, G03.0, 
G03.1, and G03.2 were used to identify the study cases. The 11-year time 
period between January 1996 and December 2006 was covered. Since the 
World Health Organisation International Statistical Classification of Diseases 
and Related Health Problems (ICD) coding system changed in 1996, we chose 
a different time period in the patient study, to avoid the potential bias 
caused by two different coding systems.
Clinical examination: A questionnaire designed for this study (including 
questions about general symptoms, musculoskeletal and neuropathic pain, 
infections, treatments, and symptoms during and after meningitis episodes) 
was used to interview the patients. All patients underwent a detailed clinical 
neurological examination. 
Laboratory tests: Plasma concentrations of IgM, IgA, IgG, and IgG1-4, serum 
concentrations of C3, C4 and serum classical pathway hemolytic activity 
(CH50) were measured, serological anti-HSV-1 and -2 antibody status was 
tested, C4 phenotyping, and the analyses of C4 gene copy numbers by 
isotype-specific genomic real-time PCR amplification, HLA-A, HLA-B and 
HLA-DRB1 typing, and IgG1 and IgG3 allotyping (Gm) were performed as 
described on page 51. Serological anti-HSV-1 and-2 antibody status was 
tested on the study entry day, at least one month from the latest meningitis 
episode. In addition, MBL2 genotyping was performed. In MBL genotyping, 
exon 1 of the MBL was amplified by PCR. Genotyping of codons 52, 54, and 
57 was performed by restriction fragment length polymorphism. 
All laboratory methods used in these studies (except IgG allotyping) are 
available in clinical practice. QST is in clinical use, especially when additional 
evidence of a suspected nerve lesion is needed. Skin biopsies are occasionally 
used in diagnostics of small-fiber neuropathy. In pain diagnostics, fMRI is 
still used for scientific purposes only.
statistics
Comparison between the groups was made by using the permutation test 
or Fisher´s exact test (I,III,IV). For continuous variables, Mann-Whitney U 
test or independent samples´ two-tailed test were used (I). For pairwise 
comparisons, the paired samples t-test or the Wilcoxon signed-rank test 
were used (I). Wilcoxon signed-rank test was used to compare the healthy 
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and painful side of the patients (QST and monofilament testing) in the 
fMRI study (II). fMRI data were analyzed using a general linear model (II).
The results are expressed as mean or median, standard deviation (SD) or 
interquartile range (IQR), and 95% confidence intervals (95%CI) (III). To 
illustrate information on the cumulative proportion, product limit estimate 
was used, and 95% CIs were obtained by bias corrected bootstrapping (III). 
The incidence ratios were calculated by using the exact Poisson regression 
model (IV). In HLA-analysis, no adjustment was made for multiple testing 
(IV). 
ethical aspects
All studies were approved by the Ethics Committee of the Helsinki University 
Central Hospital, and in all studies, the subjects gave a written informed 
consent.
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5. Results 
Widespread unilateral pain
The patients manifested a uniform clinical syndrome. They had long-lasting 
pain with fluctuating intensity, and exacerbations with HSV-reactivations. 
The patients often described their pain as burning, radiating or tingling. 
In clinical sensory examination, all but one presented either hypo- or 
hyperesthesia of the painful areas, when compared to the contralateral 
healthy side. The area of sensory abnormality was not always equal to the 
painful area; in half of the patients the painful area was larger. In QST, all 
patients had a side-to-side difference of more than two degrees at least in 
one sensory modality, when the healthy and painful sides were compared. 
At group level there was a significant difference observed only in the cold 
detection thresholds of the hands, where the cold detection threshold was 
lower on the painful side (Table 2). 
Based on the patients´ description, sensory status and QST-results, the 
pain resembled neuropathic, although according to the IASP definition, an 
exact diagnosis could not be made, since the painful area was not necessary 
neuroanatomically logical, and signs of a lesion or disease affecting the 
somatosensory system were uncertain. 
Skin biopsies were taken from only six patients as a pilot-study. These 
preliminary results did not support the hypothesis of the role of small 
fiber neuropathy in the patients´ clinical condition and thus the collection 
of biopsy samples was not continued. There were low values both in the 
painful and healthy side, and normal values on the painful side, with no 
uniform pattern. 
In laboratory analyses, when compared to both seropositive and 
seronegative controls, total plasma IgG3 concentration, and the frequency 
of low IgG1 or IgG3 or both, were more frequent in the patients. Anti-
HSV-2-IgG titers were higher in the patients than in the controls. When 
compared to seropositive controls, anti-HSV-2 titers were still higher in 
the patients, but plasma IgG3 concentrations, or in the frequencies of low 
IgG1 or IgG3 or both did not differ statistically -suggesting that IgG subclass 
deficiencies probably predispose to recurrent HSV infections, but not to 
pathological pain (Table 3).
In the fMRI study, during the measurement the average spontaneous pain 
on VAS-scale was 4.6/10. In this subgroup of patients, detection thresholds 
for cold and warm were within normal range, although lower in the painful 
side in quantitative sensory testing (p=0.04 for both). In monofilament 
testing, the tactile sensitivity was within normal limits, although lower on 
the painful side (p=0.04). Both the patients and the controls rated the pain 
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intensity and the unpleasantness of thermal stimuli similarly. 
In the fMRI of the control subjects, the contrast (Pain left-Warm left + 
Pain right-Warm right) showed bilateral activations in the IC, SII cortex, 
posterior parietal cortex (PCC), ACC and thalamus, and in the right frontal 
cortex, right inferior parietal cortex, right dorsolateral prefrontal cortex, 
and in the left cerebellum. In the patients the same contrast showed no 
statistically significant activations with the same threshold.
In the control subjects, when the hands were stimulated separately, the 
bilateral ICs, contralateral striatum, and parietal cortex were activated, 
and bilateral occipital and parahippocampal cortices and left sensorimotor 
region were deactivated. In the patients, separate stimulation of the painful 
and healthy hands showed only few activation areas; the contrast (Pain 
healthy-Warm healthy) showed a single cluster in DLPFC and the contrast 
(Pain painful-Warm painful) showed activations in the IC contralateral and 
in the IPC ipsilateral to the side of the chronic pain. 
In the controls, the contralateral IC responses were equally strong and 
similar in their time courses to the stimulation of the left and right hands. 
In the patients, the contralateral IC response was significantly weaker to the 
healthy than the painful hand stimulation.
In conclusion; when comparing the differences in the pain-related brain 
activations between the two groups, the patients had significantly less 
activity than the controls in the ICs of both hemispheres, ACC and thalamus. 
In addition, the activations in the same areas in the patients were weaker, 
when the healthy hand was stimulated (Figure 10).
When the activations elicted by warm stimulation were compared 
between the controls and the patients, no differences were seen in any 
brain regions. The time courses and strengths of the SI and SII responses 
were similar in both groups, independently which hand was stimulated, 
and the touch-related activation areas were similarly found in the SI and 
SII cortices and the cerebellum of both groups.
In VBM analysis, gray matter density was lower in the patients than in 
the control subjects in the ACC, and in frontal and prefrontal cortices. No 
area showed lower gray matter density in the control subjects than in the 
patients. 
The hemodynamic responses to tactile stimulation in SI and SII were 
highly similar both in patients and controls, despite the age difference 
between the groups. Also gray matter loss was significant in the patients 
compared to the controls, even when age was included as a covariate of no 
interest in the structural VBM analysis.
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Figure 10. The differences in the pain-related brain activations (Pain left-Warm left 
+ Pain right-Warm right) between the patients and the controls. The patients had 
significantly less activity than the controls in the ICs of both hemispheres, ACC and 
thalamus. The time courses of the contralateral IC responses were equally strong and 
similar in the controls to stimulation of the left and right hand. In the patients, the 
contralateral IC response was significantly weaker to the healthy than the painful hand 
stimulation.
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Modality Painful side Mean (SD)
Healthy side 
Mean (SD) P value
Arm
Cold sensation 29.9 (1.7) 30.9 (0.6) 0.01
Warm sensation 34.8 (2.6) 33.6 (0.9) 0.11
Cold pain 13.9 (12.0) 16.2 (11.3) 0.34
Heat pain 44.1 (4.6) 43.0 (4.9) 0.29
Leg
Cold sensation 29.0 (2.5) 29.5 (2.0) 0.43
Warm sensation 39.4 (3.6) 38.0 (3.2) 0.08
Cold pain 10.0 (11.2) 10.7 (11.4) 0.80
Heat pain 46.3 (4.1) 45.2 (4.0) 0.16
Table 2. Quantitative sensory testing (QST). Comparisons were made 
between the painfull and the respective contralateral areas.
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Variable Patients(N=17)
Controls
(N=51) P value
Seropositive
Controls 
(N=34)
P value
Means (95%CI)*
Age 44.1(41.0-47.2)
41.3
(30.2-53.1) 0.142
40.6
(37.7-43.6) 0.118
IgG1 (g/l) 5.9(5.2-6.7)
6.8
(2.9-13.3) 0.219
6.3
(5.8-6.7) 0.719
IgG3 (g/l) 0.26(0.20-0.32)
0.35
(0.11-0.84) 0.021
0.32
(0.27-0.36) 0.116
HSV1AbG (EIA) 75.0(42.2-107.9)
65.0
(45.0-85.1) 0.750
110.4
(89.3-131.4) 0.032
HSV2AbG (EIA) 60.4(32.0-89.0)
17.2
(6.17-28.2) <0.001
28.6
(12.2-45.0) 0.025
Per cents**
Low IgG1 24% 8% 0.100 9% 0.203
LowIgG3 35% 16% 0.097 16% 0.315
Low IgG1 or IgG3 59% 22% 0.006 29% 0.068
C4A genes (0 or 1) 19% 8% 1.00 15% 0.699
C4B genes (0 or 1) 62% 41% 0.160 38% 0.136
Any C4 deficiency 
(C4A or C4B) 81% 59% 0.139 53% 0.068
3 or 4 C4A genes 44% 51% 0.770 35% 0.756
Table 3. Immunological characteristics of the patients with widespread unilateral pain 
and the two control groups. * =Mann-Whitney test.  ** =Fisher`s exact test.
recurrent lymphocytic meningitis
Between January 1996 and December 2006, a total of 665 patients 
were treated at the Helsinki University Central Hospital for lymphocytic 
meningitis. In 37 of them (5.6%), the meningitis was recurrent. In 28 of the 
patients with recurrent disease (28/37), there was HSV-2 DNA in the CSF. 
In addition, three patients had a history of recurring genital herpes but 
no HSV-2 DNA in the CSF. Thus it may be approximated that the minimum 
period prevalence of the HSV-2 induced recurring meningitis is 2.2/100 000 
in the Helsinki and Uusimaa Hospital district. 
HSV-1 seropositivity was less common in the patients than in the controls 
(p=0.043). Anti-HSV-2 IgG titers in the patients during the asymptomatic 
period were higher than in the controls (p=0.034).
Serum IgG1 concentrations were lower (p= 0.009), and low IgG1 (p<0.001) 
levels were more common in the patients than in the controls (Figure 11). 
Patients with low IgG1 levels had 0.40 meningitis episodes per follow-up 
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year, compared with 0.20 meningitis episodes per follow-up year in the 
patients with normal IgG1 levels (incidence ratio 2.05). Despite a trend, 
serum IgG3 concentrations (p=0.078), or the frequency of low IgG3 (p=0.11) 
did not significantly differ between the patients and the controls. HLA-
DRB1*01 and HLA-B*27 alleles were more common in the patients than in 
the historical controls (p=0.009 and p=0.050, respectively) (Table 4). 
Immunological deficiencies associated to vulnerability to, or persistence 
of bacterial or viral infections, including partial or total C4B deficiency, low 
IgG1 or low IgG3, were detected in 12, 9 and 7 patients, respectively. HLA-
allotypes associated to infectious diseases including HLA-DRB1*01, HLA-
B*35 and HLA-B*27 were detected in 11, 9 and 7 patients, respectively. 
Combinations of these factors in a single patient were common (Table 5).
The sensitivity of PCR to detect HSV-2 was at its best, when the sample 
was taken during the first 2 to 5 days from the acute symptoms. During that 
time, HSV-2 DNA was present in 82% of the samples. The median leucocyte 
count during the first HSV-2 PCR positive episode was 350 (range 44-1410). 
In PCR negative cases, the leucocyte counts were lower and the samples 
were taken outside the optimal time period. 
The time between the first and second episodes varied from one to 216 
months (median 47 months). Paraesthesias, neuropathic pain, arthralgias, 
and urinary dysfunction were commonly reported during and after the 
clinical episode of meningitis. 
Figure 11.  Plasma IgG1 and IgG3 concentrations in the patients with RLM and in the 
controls. The limit of normal value has been indicated with a dashed line.
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The sensitivity of PCR to detect HSV-2 was at its best, when the sample was taken 
during the first 2 to 5 days from the acute symptoms. During that time, HSV-2 DNA was 
present in 82% of the samples. The median leucocyte count during the first HSV-2 PCR 
positive episode was 350 (range 44-1410). In PCR negative cases, the leucocyte 
counts were lower and the samples were taken outside the optimal time period.
The time between the first and second episodes varied from one to 216 months (median 
47 months). Paraesthe ias, neuropathic pain, arthralgias, and urinary dysfunction were 
commonly reported during and after the clinical episode of meningitis.
Figure 11.  Plasma IgG1 and IgG3 concentrations in the patients with RLM and in the controls. The limit 
of normal value has been indicated with a dashed line. 
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Variable Patients(N=21)
Controls
(N=62) P value
Means (95%CI)
IgG1 g/l 5.61 (3.60-9.97) 6.37 (2.88-13.3) 0.0088
IgG3 g/l 0.28 (0.17-0.68) 0.30 (0.13-0.84) 0.078
Per cents
Low IgG1 43% 8% <0.001
Low IgG3 33% 15% 0.11
C4B genes (0 or 1) 62% 39% 0.30
MBL2 structural variant carriage 
(A/O or O/O genotype) 43% 34% 0.459
MBL2 promoter variant carriage  
(Y/X or X/X genotype) 19% 40% 0.112
HLA-B*27 19% 8% 0.050
HLA-B*35 21% 13% 0.151
HLA-DRB*01 31% 13% 0.009
Table 4. Immunological characteristics of the patients with RLM and of the controls. 
* = 90 historical controls (Finn90). The statistical significance between the groups was 
evaluated either by permutation test or by Fisher´s exact test.
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Pat.
No
Meningitis
Episodes (N)
C4B
deficiency
HLA- 
DRB1*01
HLA- 
B*35
HLA- 
B*27
Low
IgG1
Low
IgG3
MBL2
insufficiency
14 2 d + + + +
20 4 d(t) ++ + +
9 13 d(t) + + + +
11 2 d + + +
15 3 d + + +
17 3 d + + +
10 4 d + + +
13 2 d + +
5 4 d + + + +
7 5 d(t) + + +
2 9 d +
21 2 d
18 5 ++ ++ + +
6 4 + +
16 7 + +
1 7 +
8 4 + +
3 4 +
19 2
4 4
12 2
Table 5. Summary of the immune deficiencies found in the patients with RLM. N 
=number of meningitis episodes. d =deficiency (1 C4B gene present), d(t) =total 
deficiency (0 C4B genes present). + = low IgG1/  low IgG3/  combined MBL2 genotype 
representing MBL insufficiency (XA/YO or YO/YO)/ one HLA-DRB1*01/ HLA-B*35/ HLA-
B*27	allele present. ++ = two HLA-DRB1*01/ HLA-B*35/ HLA-B*27 alleles present.
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6. Discussion
HsV and widespread unilateral pain
The original hypothesis was that HSV has an important role in development 
of pathological pain in patients with widespread unilateral pain. Our 
hypothesis was based on two reasons: first, in over half of the patients 
there was a positive correlation between the activity of HSV infection and 
the severity of pain, and second, during the follow-up, 80% of the patients 
reported at least moderate pain relief with antiherpetic medication. 
Viral pathogens activate glia, which is able to detect HSV via specific 
receptors. Activation of glia takes place at peripheral nerves, dorsal root 
ganglia, spinal cord, and most likely, also in the brain. Because of its viral 
properties (neuroinvasiveness, ability to maintain latency, and ability to 
reactivate from the latency) HSV is a good candidate for playing an active 
role in the glial activation, and creation of pathological pain. In addition, 
HSV has a predilection for frontal and temporal lobes, which are important 
pain-processing areas in the brain. 
When activated, glia releases proinflammatory cytokines like IL-1, IL-6, 
and TNF-α. Repeated HSV infections cause repeated bursts of cytokines. 
Pro-inflammatory cytokines enhance pain in models of inflammatory pain, 
and stimulate the production of other inflammatory mediators, including 
prostaglandins. The free nerve endings of peripheral nerve fibers respond 
to this by generating abnormal electrical activity that is interpreted as 
painful. The spread of pain may be explained by activation of glia: astrocytes 
activate distant astrocytes via gap junctions by releasing pain enhancing 
substances.51, 88, 90, 105, 125, 142, 155
HSV is among the most common viruses of human population, and a 
majority of individuals harbour a latent virus that can reactivate. Despite this, 
pathological pain induced by HSV is a rare syndrome. Certain immunological 
deficiencies, such as low IgG1 or low IgG3, or both, were more common 
in the patients, which probably made them more vulnerable to recurring 
HSV infections. Anti-HSV-2-IgG titres were higher in the patients, most 
probably reflecting an increased activity of HSV-2 recurrences compared to 
the controls. 
Besides herpes, recurrent or invasive infectious problems were reported 
by 65% of patients, and also other infections than HSV were reported 
to enhance pain - this fits the theory that in many cases, inflammatory 
mechanisms are active in chronic pain.
Three C4A genes, or a partial or complete deficiency of either C4A or C4B 
genes, were more common in the patients than in the controls, although 
the differences were not significant, probably due to the small number of 
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patients. It has been suggested that excessive amounts of C4 could possibly 
cause hyperactivation of the complement pathways, and exacerbate the 
inflammatory response at the local tissues. C4 deficiencies, in turn, have 
been proposed to lead to susceptibility to bacterial or viral infections.14 
The relation between the HSV virus and pain is still uncertain. It may 
also be that HSV functions only as a trigger, which induces glial activation. 
Frequent HSV recurrences trigger glia repeatedly, hence leading to amplified 
response and pathological pain.
the characteristics of the pain
In Complex Regional Pain Syndrome, as in many other clinical pain 
conditions, central mechanisms are doubtlessly active. However, according 
to the IASP criteria for neuropathic pain, CRPS pain is not classified as 
neuropathic. Our patients with widespread, unilateral HSV-associated pain 
share many features with CRPS patients: they describe pain in similar words, 
and during time their pain has expanded to cover larger areas, even on the 
contralateral side. At the moment, until more evidence has been gained, the 
term “possible neuropathic pain” is perhaps appropriate when discussing 
the type of widespread unilateral HSV-associated pain. However, as in CRPS 
pain, the same treatment strategies as in neuropathic pain may be used.
treatment aspects
Treatment options for neuropathic pain are still insufficient. Many patients 
have to undergo multiple drug therapy attempts, and use combinations of 
several drugs with frequent side-effects, to find anything to alleviate the 
pain. It is considered a good result, if the pain decreases by 30% from its 
original level. The problem with drugs used for neuropathic pain may be 
that they are originally targeted against neurons, instead of glial cells, which 
seem to be responsible for creation of pathological pain states.153 
A poor response to traditional drugs used in neuropathic pain 
(antidepressants, anticonvulsants and weak opioids), and poor tolerability 
to side effects was typical in the patient group. Instead, the majority of 
them responded to antiherpetic medication. These drugs decreased the 
frequency of HSV recurrences, hence possibly reducing glial activation by 
reducing inflammatory responses in the nervous system.
Four of our patients had undergone a treatment attempt by intravenous 
immunoglobulins, either because of pain or because of infectious problems. 
In two of them, the treatment reduced the pain. There are a few small 
studies concerning intravenous immunoglobulins and pain. Intravenous 
immunoglobulins reduce IL-1α and IL-1β levels in the plasma, and in a 
subgroup of patients, also reduced pain.123 Theoretically, it might be a 
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treatment option in severe cases. However, in lack of good evidence, poor 
availability and high price, it will never be a treatment option to larger 
patient groups. 
We already have a few drugs with an ability to inhibit microglial 
activation. Some of them are even in clinical use, although not in pain 
patients. One of these drugs is minocycline, which is an old drug, a 
semisynthetic tetracycline derivative. Besides antimicrobial actions, it 
has neuroprotective properties. It prevents apoptosis, reduces microglial 
activations, and prevents the release of proinflammatory cytokines.105, 132 
It has proved effective in animal studies in several models of different 
neurological diseases.78 In humans, minocycline significantly reduced white 
matter lesions in MS patients.156 Minocycline is a safe and cheap drug with 
high tolerability, but at the moment it is not commercially available in 
Finland.
Another drug possibility is ibudilast (AV411), which has been used in 
Asia to treat asthma, and stroke-related dizziness. Ibudilast suppresses 
proinflammatory cytokines and increases anti-inflammatory IL-10 in CNS 
glia.143 Also ibudilast has been in clinical use for years, and has high safety 
and tolerability. There has been a small study enrolling about ibudilast in 
diabetic neuropathic pain, but no results are available as yet.
changes in functional brain imaging
Both functional and structural brain abnormalities were observed in 
the patients with chronic unilateral widespread pain. When compared 
to controls, the pain-related responses were attenuated in several pain-
processing areas. Also gray matter density was decreased in areas related 
to pain-processing.
Acute experimental and clinical pain elicit different responses in 
functional brain imaging studies. It has been suggested that pain-related 
responses attenuate more in clinical than in experimental pain. In clinical 
pain, emotions, fear and anticipation of pain are more profoundly involved 
than in experimental pain. It has also been suggested that in clinical pain, 
pathways outside the spinothalamic tract, such as spinoparabrachial tract, 
spinohypothalamic tract, and spinoreticular projections are becoming more 
important. In addition, it is probable that different clinical pain states 
generate different brain activation patterns.8, 133
There is a balance between facilitatory and inhibitory systems of pain, 
and in chronic pain this balance probably changes. The inhibitory and 
facilitatory tracts of the spinal cord have been investigated for years. It 
is probable that also cortical areas are involved in pain facilitation and 
inhibition. Both activation and deactivation of cortical areas may be crucial 
in cortical pain-processing. Deactivation of cortical areas might reflect 
a reduction in neuronal activity. Deactivation of inhibitory areas in the 
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brain may theoretically be one of the causes of chronic pain. It has been 
shown that gabapentin reduces pain-related deactivation in chronic pain, 
suggesting that deactivation may contribute to chronic pain.59, 113, 157 
Decrease in gray matter density has previously been associated to both 
HSV virus and the pain itself. HSV is neuroinvasive and able to reactivate in 
the CNS after latency. It prefers the frontal and temporal lobes, and has been 
shown to cause gray matter loss during encephalitis. On the other hand, 
gray matter loss has been described in pain conditions like fibromyalgia, 
and chronic back pain. It is impossible to say definitely whether gray matter 
loss in our patients is associated to HSV or pain, or both. On the other hand, 
decrease in gray matter density and reduced neuronal activity might be one 
explanation to attenuated pain responses in pain processing areas.
Unfortunately, age- and sex matched controls for fMRI and VBM analysis 
were not available. This is a drawback, because ageing is associated with 
changes in the hemodynamic response strength and decreased gay matter 
density. However, the hemodynamic responses to tactile stimuli were similar 
between the patients and the controls, which makes significant age-related 
differences between the groups unlikely. In VBM analysis, age was included 
as a covariate of interest to render the effect of age-difference between 
the groups.
Previously cortical reorganization has been observed in association with 
both extensive training, and loss of sensory input.35 Cortical reorganization 
itself may cause chronic pain, and a reduction in CRPS pain has been shown 
to correlate with a recovery from cortical reorganization.81 Eight of the 
patients with widespread unilateral pain (the same patients as in the fMRI 
study) also underwent MEG recordings.141 In seven out of eight patients, the 
D1-D5 distance (cortical representation areas to fingers 1-5) was shorter to 
the stimulation of the painful than the non-painful hand. There were no 
differences in fine motor skills between the hands, and no signs of damage 
to the sensory system in electrophysiological studies were observed, hence 
supporting the hypothesis that cortical reorganization may occur also in the 
absence of deafferentation, and may be associated with pain itself. 
The characterization of this clinical syndrome seemed to be especially 
important to the patients themselves. Until this, the patients had been 
rigorously examined by laboratory, electrophysiological and imaging 
methods. Those methods had revealed some abnormality (e.g. entrapment 
of the ulnar nerve in a patient with a pain in the whole left side of the 
body), but did not sufficiently explain the spread of pain. This had even led 
to suspicion of only psychological reasons behind the pain. Although we 
are still unable to give an exact reason for the pain, the patients perhaps 
feel that they have been better understood. 
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Limitations of the study
The nature of pain in our patients remains uncertain. During the time of 
the study, we did not have detection questionnaires concerning neuropathic 
pain in Finnish. We should have included the McGill Pain Questionnaire to 
our study, which in part would have helped us to classify the pain. 
The duration of pain in the patients varies. In some patients, the pain was 
at its most intensive phase, while others though that the pain had alleviated 
when compared to the worst phase. This difference most certainly affects 
to the results in the clinical sensory examination, in the QST, and possibly 
in the fMRI also.
At individual level, the side-to-side differences in the QST were 
remarkable. However, at the group level these differences were not 
significant. This is likely due to the small number of patients, and on the 
other hand, to a large variation of the sensory detection thresholds even 
on the healthy size. The patients were supposed to have abnormality in the 
cortical procession of pain – this may cause changes also in the procession 
of painful stimuli delivered to the healthy side. For that reason, age- and 
stimulus-location matched controls should have been used.
In the fMRI study, it would have been ideal to study a larger patient 
group. However, we did not have that possibility; the original patient group 
from where the patients were selected from was small, and when deciding 
to study patients as similar pain distribution as possible and with a similar 
sensory phenomenon, we ended up to a small patient cohort. In an ideal 
situation, a cohort of 16-20 patients would have given more reliable results. 
Also, the controls we used in the fMRI study should have been collected 
more carefully. Controls in the fMRI and VBM analysis were significantly 
younger than the patients. Although the similar tactile responses between 
the patients and the controls exclude major differences in pain-related 
responses, caution in the interpretation of the results should be used. In the 
VBM analysis, age was included as a covariate of no interest to minimize 
the effect of age difference between the groups.
In conclusion; the possibility of inflammatory mechanisms in chronic pain 
should be considered in clinical practise. Infectious problems in patients with 
chronic pain should be evaluated, and treated by antibiotics or antiviral 
medication when needed. Clinical studies about the drugs with possible 
effect on glial activation would be beneficial.
Prevalence, clinical symptoms and predisposing factors 
in RLM
The exact prevalence of HSV-2 induced RLM is difficult to determine, since 
patients may have long asymptomatic periods between the episodes of 
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meningitis. The time between the first and second meningitis episode varied 
from a few weeks to more than ten years. For that reason, we used the 
term “period prevalence”. Only in one earlier study an approximation of 
the prevalence of RLM has been given, which was 1/100 000. In our study 
the prevalence was higher, 2.2/100 000. 
The diagnostic accuracy of the disease has increased during the last two 
decades because of the PCR method, which at least partially explains the 
increase in the prevalence ratio. On the other hand, in developed countries, 
seroprevalence of HSV-1 has declined, while that of HSV-2 has increased. 
Hence, a greater proportion of HSV-2 infections are primary instead of 
initial. In primary HSV-2 infections, complications (meningitis) after the 
disease (genital herpes) may be more frequent than in initial infections. This 
may be another explanation for the increase in the prevalence of RLM.22
Associated symptoms
RLM is less benign than previously reported: neuropathic pain, paraesthesias, 
arthralgias, and urinary dysfunction were common during and after 
meningitis, and the symptoms often lasted for months and even years 
before full recovery. In meningitis, the infection is not limited to meninges 
around the brain, but also to meninges around the spinal cord and spinal 
nerves may be affected. This explains the associated symptoms like radicular 
pain, paresthesias, and urinary difficulties. When clinical signs of myelitis 
were involved, the time of recovery was longer. Traditionally, RLM has been 
described as a benign disease with no neurological sequlae – and if not, this 
diagnosis should be excluded.116 Our results challenge this view.
Laboratory diagnostics
The PCR method is considered a gold standard in diagnosis of CNS infections. 
It is known that almost 90% of cases of RLM are caused by HSV-2 virus. Still, 
HSV-2 DNA is not always found from the CSF despite earlier HSV-2 DNA 
positive samples. In our study, the lowest leucocyte count in HSV-2 positive 
samples was 44 leucocytes in mm3. Similar sensitivity of the PCR method 
has been reported in other studies, too. Although the PCR method today is 
more sensitive than a few years ago, false negatives may result if the timing 
of a sample is early, and there are only a few leucocytes in the CSF. In those 
cases, PCR analysis should be performed from a CSF sample taken during 
the optimal time period, 2 to 5 days from the first symptoms.
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treatment aspects
Due to well tolerated antiherpetic medication, either intravenous or peroral 
antiviral medication may be recommended during acute meningitis episodes, 
as it seemed to shorten the acute phase of the disease, and alleviate the 
acute symptoms. Prophylactic antiviral medication seemed to decrease 
the number of meningitis episodes, but was not universally effective. 
Prophylactic treatment should be considered at least when the patient has 
frequently recurring symptomatic HSV-2 infections – although benign in 
nature, recurrent HSV infections decrease the quality of life. The patients 
with low IgG1, and HLA-B*27 or HLA-DRB1*01 alleles might be considered 
to have an increased risk for a new RLM episode. Especially those high risk 
patients might benefit from the prophylactic antiviral therapy.
Predisposing factors
We found several potential predisposing factors for RLM. Low IgG1 was 
more common, and there was also a trend of low IgG3 being more common 
in the patients than in the controls. Low IgG1 and IgG3 may increase 
the patients´ vulnerability to HSV-infections and their complications by 
diminished ADCC activity. It is probable that low IgG1 or IgG3 are not 
independent risk factors for RLM, but rather risk factors for more frequent 
or severe symptomatic HSV-2 infections, or a more severe primary infection, 
which increases the risk of meningitis.
MHC genes have been associated with more than 100 diseases. The 
causative genes responsible for the disease associations are difficult to 
identify, and usually large population based studies are needed. Despite 
the small number of patients we showed that HLA-DRB1*01	and	HLA-B*27 
were more common in the patients than in the controls. The prevalence of 
HLA-DRB1*01 (53%) in affected individuals is among the highest reported 
thus far in any patient population suffering from HLA-associated diseases. 
Previously HLA-DRB1*01 has been associated with peridontal pathogens in 
Finnish coronary artery disease patients, and HLA-B*27 and HLA-B*35 with 
infectious or post infectious complications in chronic HSV infections, HIV, 
reactive arthritis, and Chlamydia	pneumonie infections. 
Combinations of the factors which potentially affect to immune responses 
(complement C4B deficiency, low IgG1 and IgG3, and HLA-DRB1*01, -B*35 
and B*27)  were common among the patients. Two patients had five of 
these factors, seven patients presented four, two patients three, four 
patients two, three patients only one, and three patients showed none of 
these factors. It may be that single deficiencies do not increase susceptibility 
to infections, but the combined influence of multiple subtle impairments 
may be clinically relevant. 
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In conclusion; in patients with a second episode of aseptic lymphocytic 
meningitis, the aetiologic agent in most often HSV-2. PCR may be insensitive, 
if the leucocyte count in CSF sample is too low. Patients do not always totally 
recover from meningitis within a few weeks. Antiherpetic medication should 
be used due to its good effect and tolerability.
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7. CONCLUSIONS
1. Infections and inflammation may have a significant role in creating 
pathological pain states, by activating immunologically active glia in the 
CNS. Activated glia is responsible for “extra-territorial” pain, where the 
pain spreads from the original territory to larger areas. Glia is able to 
detect HSV most likely via Toll-like receptors.
2. Herpes simplex virus is neurotrophic, it is able to maintain latency in the 
CNS, and able to reactivate periodically. HSV is thus a good candidate to 
activate the glia.
3. Functional brain imaging reveals attenuated pain-related responses and 
decreased gray matter density in the pain-processing areas in patients 
with widespread unilateral HSV associated pain. Attenuation of pain-
related responses has previously been described most often in chronic 
pain. Gray matter loss may be associated to chronic pain, HSV infections, 
or both, and may also be one explalation for the attenuation of pain-
related responses.
4. Immunoglobulin G subclass deficiencies may predispose to frequent HSV 
recurrences and to HSV associated diseases, including RLM. Frequent HSV 
recurrences may predispose to pathological pain.
5. RLM is more common and less benign than previously reported, and the 
prevalence of RLM may increase in the future.
6. In addition of low IgG1 subclass, predisposing factors to RLM include 
HLA-DRB1*01 and HLA-B*27. The combined influence of multiple subtle 
impairments may be clinically relevant.
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